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ABSTRACT
Introduction: The primary study goal was to assess the feasibility of implementing a
Randomized Clinical Trial (RCT) of Mindfulness-Based Relapse Prevention (MBRP) in
a substance use and methadone clinic using a neuropsychological framework.
Methods: Participation interest, retention rates, and feasibility of study design were
examined. 13 participants were randomized to waitlist (n = 6) or MBRP (n =7).
Associations between baseline variables and retention were examined. Executive function
(EF) performance and topological properties of fNIRS resting-state networks were
assessed.
Results: Power was limited, but quantity of outside treatment was associated with
retention. EF was variable, but within the average range. Network analyses revealed
small world parameters in resting-state networks using fNIRS. Exploratory correlation
analyses between EF and graph metrics were performed.
Conclusions: The feasibility of using neuropsychological measures of EF and fNIRS in
the context of a RCT in an outpatient substance use clinic was demonstrated.
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INTRODUCTION
Each day roughly 130 people will die following an opioid overdose in the United
States; and these rates continue to rise (NIDA, 2019b). Between 2016 and 2017 overdose
deaths from fentanyl, for instance, increased by 45 percent (Scholl, Seth, Kariisa, Wilson,
& Baldwin, 2018). The rate of overdose deaths associated with opioids in New Mexico
remains well above the national average (NIDA, 2019a). Opioid Use Disorder (OUD) has
been associated with increased psychiatric and comorbid substance use problems. In
particular, previous use of other substances of abuse appears to be the norm rather than
the exception. For instance, while a prior anxiety disorder diagnosis increased the odds of
later developing an OUD by 50%, a prior substance use disorder (SUD) diagnosis
increased the odds of developing an OUD by 300% (Blanco & Volkow, 2019). While
medical interventions may be the first line of treatment for OUD, given the chronic and
relapsing nature of OUD, behavioral interventions are needed particularly after patients
are stabilized. Despite a significant need for more effective interventions, there remains a
significant gap in the literature on the best psychosocial interventions (Dugosh et al.,
2016).
There is clear need for additional treatment approaches for OUD. Advances in
neuroimaging and clinical neuroscience have fueled interested in identifying new
treatment targets for OUD via a neuropsychological approach (Ieong & Yuan, 2017;
Stewart, May, Aupperle, & Bodurka, 2019). A neuropsychological framework to mental
health can help identify new targets for treatment and assess changes in those markers
over time through the use of neuropsychological assessments, neuroimaging methods and
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self-reported symptoms. Following a brief overview of current treatments for OUD, a
neuropsychological framework will be employed for the remainder of the paper.
Opioid Use Disorder: Treatment As Usual
Broadly, OUD treatments can be divided into three different approaches based on
the treatment goal: crisis intervention (in context of overdose), medicationassisted/maintenance treatment, and abstinence-based intervention(Hser, Evans, Grella,
Ling, & Anglin, 2015; Van den Brink & Haasen, 2006). While crisis intervention is
beyond the scope of this paper, it is worth noting that this stage of treatment is when most
individuals with an OUD seek treatment, with one in four individuals seeking additional
treatment in the following month. Abstinence-oriented interventions occur in two phases:
detoxification and relapse prevention. In general, treatment outcomes have been
disappointing and appear effective for a relatively small subset of individuals with OUD
with high social support, stable environments and high levels of motivation (Van den
Brink & Haasen, 2006). Medication-assisted treatments (MAT)have greater success rates
and emphasize a harm reduction approach to treatment. MAT involves one of three FDAapproved medications: methadone, buprenorphrine, and naltrexone(Connery, 2015). All
three medications target the mu-receptor: methadone is a full agonist, buprenorphrine is a
partial agonist, and naltrexone is an antagonist. In a recent review of RCTs of
methadone, buprenorphine and naltrexone, the efficacy of these medications for
prevention of opioid relapse and continuation in treatment has been
demonstrated(Connery, 2015). Of the three, Methadone remains the gold standard for
OUD treatment.
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Methadone Maintenance Therapy (MMT), a type of opiate replacement therapy
(ORT), has been associated with decreased likelihood of overdose, reduced contraction of
HIV/Hepatitis C among intravenous drug users, and has been shown to enable individuals
to have more functional lives through reduction of criminal risks and increased ability to
gain employment (WHO, 2009). Despite this success, mortality rates in long-term cohort
studies of individuals receiving methadone, nonetheless, were 6 to 20 times greater than
that of the general population, and 25-50% of the cohorts were deceased 20 years after
baseline (Hser et al., 2015). The authors suggest mortality rates were impacted by AIDS
among areas with high HIV prevalence, and impacted by suicide and trauma in countries
with lower rates of HIV/AIDS (Hser et al., 2015).
A number of behavioral interventions have been used in conjunction with MMT
and include: contingency management, 12-step recovery, cognitive behavioral therapy,
motivational interviewing, risk reduction counseling, Acceptance and Commitment
Therapy (ACT), general therapy, and supportive counseling (Dugosh et al., 2016).
However, most research has focused on contingency management and cognitive
behavioral therapy in conjunction with methadone maintenance (Dugosh et al., 2016).
While research has supported the incremental value of using behavioral interventions in
conjunction with ORT, success varies based on treatment outcomes and comparison
groups.
A significant majority of individuals reporting symptoms of OUD report no
treatment (L. T. Wu, Zhu, & Swartz, 2016). Given the risks associated with OUD this is
concerning. Further, even among individuals that eventually seek treatment, most
individuals reported use of opioids 6 to 10 years before initiating treatment (Hser et al.,
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2015). In addition to the limited access to treatment and delays in treatment seeking,
among patients that initiate treatment, there are high drop-out rates that are concerning.
Research has shown that patients that remain in MMT for longer periods of time have
better treatment outcomes. The first year of treatment appears to be especially critical
(Hser et al., 2015). However, there is a vast literature suggesting the majority of patients
drop out of treatment in the first year. Furthermore, in outpatient settings, drop-out rates
are even higher than in randomized controlled trials (Roberts, 2018). Efforts to identify
and ameliorate barriers to treatment are of great interest. In particular, individuals using
prescription opioids and individuals who are adolescent or from ethnic minority
backgrounds are less likely to receive care (F. Wu, Fu, & Hser, 2015). There is a
significant need to target prevention and treatment efforts towards these populations.
Concerns with Treatment As Usual
While ORTs have undoubtedly reduced rates of overdose deaths and contraction
of HIV/Aids and Hepatitis C, the high rates of drop and low treatment engagement
suggest more can be done to improve treatment. The MMT phase of treatment may last
for years or for the patients’ life. There remains among providers, a debate as to whether
efforts should be made to facilitate discontinuation of methadone treatment or whether it
should remain a lifelong option (Schuckit, 2016). On the one hand, some individuals
seeking ORT may perceive it as an alternative to criminalization (Frank, 2018),
alternatively, for individuals seeking to eventually discontinue methadone, this may not
be perceived as a good fit either.
ORT is generally provided at outpatient substance use clinics, methadone clinics,
or inpatient substance use settings. Access to specialty clinics may be an additional
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barrier, particularly among individuals with limited transportation or those that live in
rural communities (Amiri et al., 2018; Sigmon, 2014). Alternative models of care
including, primary-care-based models have been explored, with the hope of increasing
access to care (Korthuis et al., 2017). Even among individuals receiving treatment at
outpatient substance use clinics, there has been concern that individuals are not always
prescribed the most effective medication or are prescribed doses that were below the
effective dose. In 2011, for instance, in a nationwide sample of patients on MMT, 41
percent of the sample received doses that were too low to be optimally effective
(D'Aunno, Park, & Pollack, 2019).
Historically, under-dosing of methadone had been a clinical concern. Notably
while this pattern has improved within the general population, among ethnic minorities
this remains a significant clinical concern (D'Aunno et al., 2019). Further, treatments
may not adequately serve all individuals. Research assessing gaps in access to care has
found that individuals from different cultural backgrounds may find the MMT approach
inadequate. For instance, a recent qualitative study interviewed 53 Latino and African
American individuals that were using intravenous drugs but had declined to continue
receiving treatment at a methadone clinic (Zaller, Bazazi, Velazquez, & Rich, 2009). The
authors identified specific beliefs related to discontinuing treatment, including belief that
methadone was harmful to one’s health, perception that methadone should be
discontinued, and belief that one cannot be abstinent from substances of abuse if on
MMT. Additionally, financial burden and the time requirements for treatment were
barriers noted.
Opioid Use Disorder Complexity
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ORT may not sufficiently address the range of complexity observed within this
population. While substance use disorders are diagnosed for the individual substance of
abuse, instances of comorbid substance use disorders remain a clinical issue. A recent
publication using the National Epidemiological Survey on Alcohol and Related
Conditions (NESARC) data examined prevalence of multiple substance use disorder
diagnoses at two time points (McCabe & West, 2017). The authors found individuals
diagnosed with multiple SUDS at time point one were more likely to exhibit a SUD at
time point two, relative to individuals diagnosed with one SUDs at time point one.
Further, the authors found individuals with multiple SUDs were less likely to receive any
SUD treatment relative to individuals with a single SUD (McCabe & West, 2017).
Among OUD samples, research from the 2015-2017 National Survey on Drug Use and
Health data found significant rates of co-occurring drug and alcohol use among adults
diagnosed with an OUD (Jones & McCance-Katz, 2019). More specifically, the rate for
co-occurring SUDs ranged from 26.4% for alcohol to 10.6% for methamphetamine
(Jones & McCance-Katz, 2019). Among individuals with OUD, 57.3% met criteria for
polydrug use disorder, with alcohol as the most frequently reported substance used in
addition to opioids (Hassan & Le Foll, 2019). Further, polydrug use among individuals
with an OUD may be associated with greater psychopathology, including PTSD (Hassan
& Le Foll, 2019). While polysubstance use disorder was not included in the latest
iteration of the Diagnostic and Statistical Manual of Mental Disorders (DSM), use of
multiple substances, particularly among OUD clients remains an important clinical
concern.
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Adults with an OUD exhibit elevated rates of psychopathology. More specifically,
64.3% of adults with an OUD experienced mental illness in the past year and 26.9%
experienced serious mental illness within the past year (Jones & McCance-Katz, 2019).
Among those individuals with OUD that experienced mental illness in the past year,
24.5% reported receiving treatment for both substance and mental health concerns, while
29.6% of individuals with OUD and serious mental illness reported receiving treatment
for both conditions. Among a sample of treatment seeking individuals with a SUD, 32%
reported a past suicide attempt and of those, 59% reported a serious attempt (Icick et al.,
2017). Clearly, more comprehensive interventions that address the complexity of OUD
are needed.
While ORTs have the potential to greatly improve the lives of individuals with an
OUD, they are unfortunately underutilized. In part, perhaps, because ORTs do not
address the prevalent comorbid substance use and mental health concerns in this
population. Interventions are needed that can simultaneously address substance abuse
and comorbid mental health issues. Mindfulness-Based Interventions (MBIs) show great
promise in this respect.
Mindfulness-Based Interventions (MBIs)
MBIs are being increasingly used in the treatment of a wide range of psychiatric
conditions (Alfonso, Caracuel, Delgado-Pastor, & Verdejo-Garcia, 2011; Hofmann,
Sawyer, Witt, & Oh, 2010; Witkiewitz & Bowen, 2010). The vast majority of MBIs are
based on Mindfulness-Based Stress Reduction (MBSR) during which individuals learn
ways to practice techniques to increase mindfulness, defined broadly as “…paying
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attention in a particular way: on purpose, in the present moment, and nonjudgmentally”
(Bowen, Chawla, & Marlatt, 2011).
MBIs have shown efficacy for individuals with SUDs and have been shown to
reduce both substance use behavior and self-reported craving across a variety of
substance-using samples (Bowen et al., 2014; Chiesa & Serretti, 2014; Witkiewitz &
Bowen, 2010; Witkiewitz et al., 2014). One prominent approach, Mindfulness-Based
Relapse Prevention (MBRP) has been shown to reduce craving and prevent relapse in
individuals with an SUD via improved mood (Witkiewitz & Bowen, 2010) and
acceptance of thoughts (Witkiewitz et al., 2014).
Implementing MBRP within an outpatient methadone clinic is relatively novel.
Recently, Bowen and colleagues (2017) conducted a pilot study of clients receiving
treatment at a MMT clinic (Bowen, Somohano, Rutkie, Manuel, & Rehder, 2017). In that
study, 15 individuals completed the baseline visit, and seven completed the follow up
visit. Participants in the study were recruited from a community-based methadone clinic.
Average age of the sample was 43.8 years (ages 27 to 65 years old), the majority of the
sample were white (93%) and employed full-time (87%). Regarding clinical variables,
over half had a history of inpatient substance use treatment and the majority of the
sample was concurrently participating in a 12-step program. Preliminary results based on
direction and magnitude of mean change suggested improvements in outcome associated
with MBRP. The largest effect size was for change in craving (g = 0.98, p = .032).
Medium effect size for change in mood and a smaller effect size for change in traumarelated symptoms was also found (g = 0.63, p = .03; g = 0.09, p = .025). A second study
examined the impact of MBRP on relapse and self-report ratings of impulsivity among
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patients receiving MMT (Yaghubi, Zargar, & Akbari, 2017). Seventy patients referred to
MMT centers in Iran were randomized to receive either, treatment as usual (TAU) or an
8-week MBRP group. Lower rates of relapse were observed in the MBRP group
immediately following the intervention (p = 0.012) and at a two month follow up visit (p
= .010).

Relative to the TAU group, the MBRP group scored significantly lower on a

self-report measure of impulsivity, the Barrett Impulsivity Scale (BIS-11) (p < .001),
immediately following the intervention. The drop in self-reported impulsivity remained
two months following the completion of the intervention. While potential mechanisms of
action associated with MBRP are still being explored, executive function (EF), which
includes impulsivity, has shown great promise as a possible treatment target for SUDs
and as a possible mechanism by which MBIs work.
Definitions and Measures of Executive Function
Broadly, executive function (EF) refers to a set of interrelated cognitive processes
that enables one to carry out goal-directed behavior and inhibit prepotent (automatic)
responses (Kramer et al., 2014; Lezak, Howieson, & Loring, 2004; Miyake et al., 2000).
Various models of EF have been proposed. One distinction that has particular application
to SUD is that of “cool” EFs and “hot” EFs. Namely, while “cool” EF refers to abilities
in a context-free environment, “hot” EF refers to those abilities in affective contexts
(involving emotion, motivation, reward). Typically, the EF tasks used in lab and clinic
settings are “decontextualized”, meaning they do not have an “affective or motivational
component” (Prencipe et al., 2011).
Miyake and Friedman’s model of EF (Miyake et al., 2000), a well validated,
developmentally relevant model of EF captures the cool EFs, including: updating,
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shifting, and inhibitory control. While this model was originally tested within typically
developing adults, a longitudinal study examining individuals performance on measures
of EF during late adolescence and young adulthood, found the unity/diversity model of
EF was supported (Friedman et al., 2016).
Cool EF can be measured with neuropsychological tasks that measure: updating
and monitoring working memory; shifting between tasks or mental sets; and inhibiting
dominant or prepotent responses (Miyake et al., 2000). Given the multifactorial nature of
EF, a single score on a test does not sufficiently capture the construct of interest, which,
in part motivated the creation of The Delis-Kaplan Executive Function System (DKEFS), a widely used battery of EF tests.
In more recent years, efforts to develop computerized tasks of EF have been
made. The National Institute of Health (NIH) Toolbox for the Assessment of
Neurological and Behavioral Function (NIH-TB) Cognitive Battery measures EF across
the lifespan at multiple time points. The Toolbox contains multiple measures of EF that
map well onto Miyake and Friedman’s model of EF, including: Dot Counting and N-back
(updating), Set Shifting (shifting) and Flanker (Kramer et al., 2014; Macleod, 1992).
Hot EFs continue to develop during late adolescence into young adulthood and
involve: affect intensity and reactivity (having to do with the initial affective response)
and affective modulation, cognitive modulation and behavioral control (domains more
related to top-down control of emotion) (Wilcox, Pommy, & Adinoff, 2016). Hot EF can
be measured with self-report and tasks that measure: negative affect, reactivity, and
coping with emotions. Examples of tasks and self-report measures of hot EF include:
Difficulties in Emotion Regulation Scale (DERS) and White Bear Suppression Index
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have been tied to hot EF in substance use disorders (H. C. Fox, Axelrod, Paliwal, Sleeper,
& Sinha, 2007; H. C. Fox, Hong, & Sinha, 2008; Garland, Carter, Ropes, & Howard,
2012; Toll, Sobell, Wagner, & Sobell, 2001).
The neuroanatomical correlates of EFs have been examined using both structural
and functional neuroimaging studies (Friedman & Miyake, 2016). While EF typically
involves multiple brain regions, they are often associated with the prefrontal cortex (PFC)
(Otero & Barker, 2014; Stuss & Alexander, 2007). Based on lesion studies, cool EFs are
frequently localized to dorsolateral PFC and the anterior cingulate cortex, hot EFs are
typically localized to ventromedial PFC (Robinson, Calamia, Glascher, Bruss, & Tranel,
2014). There is some evidence to suggest specific properties of neural networks may be
correlated with specific EFs, as well (Reineberg, Gustavson, Benca, Banich, & Friedman,
2018).
Neurodevelopmental Correlates of Executive Function
Many of the neurodevelopmental changes that occur in the PFC during
adolescence and young adulthood have been linked to the protracted development of EF
(Asato, Terwilliger, Woo, & Luna, 2010; Barnea-Goraly et al., 2005; Squeglia, Jacobus,
Sorg, Jernigan, & Tapert, 2013). Substance use during adolescence and young adulthood
has the potential to disrupt these developmental processes in clinically significant ways.
In particular, EF development during adolescence has been associated with
increased within-PFC connectivity, increased PFC activation at rest and during EF tasks,
as well as changes in the topological features of connectivity (Fair et al., 2007).
Developmental changes in within-PFC connectivity can be observed in both structural
connectivity and functional connectivity. For instance, during adolescence increasing age
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is positively correlated with increasing structural integrity of white matter within the
prefrontal cortex (Barnea-Goraly et al., 2005). Further, white matter connectivity in tracts
connecting PFC to PFC (e.g., genu of the corpus callosum) continue to develop during
adolescence (Asato et al., 2010). Functional connectivity analyses provide further
support. For instance, decreased short-range connectivity and increased long-range
connectivity and reduced white matter integrity of the genu of corpus callosum has been
associated with higher scores on a self-report measure of EF behaviors (Clark, Chung,
Thatcher, Pajtek, & Long, 2012).
SUDs have been associated with aberrant development of these neurobiological
pathways. Further, given the increase in substance use during adolescence, the use of
drugs and alcohol also directly impact the development of the neural circuits underlying
EF. While additional deficits have been associated with SUD, broadly, EF in particular is
tied to neurodevelopmental changes that occur during adolescence and have significant
correlates. Functional neuroimaging methods are able to detect the functional
connectivity between brain regions. Functional Near-Infrared Spectroscopy (fNIRS) is an
approach that has great promise.
Functional Near-Infrared Spectroscopy (fNIRS)
fNIRS is a non-invasive, functional neuroimaging technique that infers changes in
neural activation via changes in oxygenation levels and blood flow in the brain. When
neural activity increases in response to a task there is an increase in the cerebral blood
flow (CBF) to the brain region involved. When there is an increase in CBF to an area of
the brain fNIRS detects an increase in the ratio of oxygenated hemoglobin relative to
deoxygenated hemoglobin in that region of the brain (i.e., the hemodynamic response)
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(Tachtsidis & Scholkmann, 2016). More specifically, the fNIRS device emits light of
varying wavelengths that penetrates approximately one to two centimeters into the
cerebral cortex. Oxygenated blood (HbO2) and deoxygenated blood (Hb) absorb different
light wavelengths of electromagnetic radiation. Based upon the properties of the tissue
the light is then scattered at different rates. The scattered light is then detected by the
fNIRS device and based upon how much light was absorbed one can infer differences in
hemoglobin concentration. More specifically, greater light absorption suggests increased
blood flow to that brain region (i.e. greater deoxygenation) which is thought to reflect an
increase in neural activity in cortical regions of the brain.
Relative to alternative neuroimaging methods, fNIRS has a number of advantages
(Cui, Bray, Bryant, Glover, & Reiss, 2011). First, compared to fMRI, fNIRS is relatively
inexpensive and simple to use, making it ideal for longitudinal studies that assess
treatment effects. Further, motion artifacts are less of a concern with fNIRS making it a
useful alternative to fMRI among adolescents. Finally, fNIRS is portable and can be used
within an office or hospital setting making it a convenient and ecological valid approach
for clinical populations (Noah et al., 2015).
A variety of different analytical methods have been applied to fNIRS data. In
addition to detecting changes in activation in a given region of the brain, recent studies
have used fNIRS to explore properties of neural networks in the brain using Complex
Network Analyses (Fekete, Beacher, Cha, Rubin, & Mujica-Parodi, 2014). Efforts to
apply functional connectivity analytic methods have been particularly promising. In
particular, the properties of resting state networks may provide insights into potential
biomarkers of substance use disorders as well as associations with EF. Resting state
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networks have frequently been studies as potential endophenotypes associated with
different psychiatric issues. Resting state networks can be studied using a variety of
different statistical methods. For this study, a graph analytic approach was utilized to
characterize various topological properties of the fNIRS resting state networks. Graph
theory is a branch in mathematics concerned with the study of networks. Recent work has
applied graph theory techniques to structural and functional neural networks (Bullmore &
Sporns, 2009). Briefly, graphs can be used to describe a complex network by
characterizing it as a set of nodes or vertices, connected to one another by a subset of
edges (Bullmore & Sporns, 2009). Specific topological properties of the graph can then
be calculated at a global level (the entire network), at a nodal level (properties of a given
node in the network), and at a modular level (clusters of densely connected nodes within
the network).
Relative to random graphs, graph of brain networks have higher clustering and
more variable degree centrality at each node (i.e., more variability in the number of
connections between a given node and the rest of the regions in the network). Brain
networks have been found to have high clustering and shorter path lengths, a
phenomenon referred to as “small worldness”. Path length and global efficiency are
measures believed to capture the integrative nature of a network (Papo, Buldu, Boccaletti,
& Bullmore, 2014).
Graph theory analyses have been shown to predict meaningful properties of how
the brain networks across a range of populations and has been utilized in efforts to
identify potential endophenotypes that may serve as future treatment targets. In sum,
fNIRS has the potential to assess changes in the BOLD signal in a given region, as well
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as, changes in FC between regions of a neural network (M D. Fox & Raichle, 2007; M.
D. Fox et al., 2005).
fNIRS and Executive Function
fNIRS has been used to explore neurobiological correlates associated with EF. In
healthy controls, increased oxyhemoglobin was observed in bilateral DLPFC during
interference trials of the Stroop task (Schroeter, Zysset, Kruggel, & von Cramon, 2003).
In a different sample, the switching condition of the Stroop was associated with greater
activation in bilateral anterior DLPFC and bilateral anterior VLPFC activation (LagueBeauvais, Brunet, Gagnon, Lesage, & Bherer, 2013). Further, variability in EF
performance has been associated with variability in oxyhemoglobin changes during an
EF task in children, providing further support that changes in EF can be detected with
fNIRS (Schroeter, Zysset, Wahl, & von Cramon, 2004). fNIRS has also been used to
explore EF impairments in clinical samples. For example, compared to healthy controls,
adults with EF impairment (diagnosed with ADHD), exhibit less oxy-hemoglobin
increases in the ventrolateral PFC during a working memory task (Ehlis, Bahne, Jacob,
Herrmann, & Fallgatter, 2008). Finally, fNIRS has been used to improved diagnostic
accuracy rates (Monden et al., 2015). More specifically, using pattern classification
methods, neural activation during an inhibitory control task improved diagnostic
accuracy rates in a sample of children with ADHD and typically developing controls.
The clinical applications of fNIRS have only recently being explored. However,
fNIRS has been shown to be informative in predicting treatment outcomes for EF. For
instance, fNIRS was used to assess changes in oxyhemoglobin in the PFC following an
exercise intervention for EFs. Results showed the changes in PFC function explained a
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significant proportion of the variance associated with EF improvement (Lambrick,
Stoner, Grigg, & Faulkner, 2016). Lastly, fNIRS has been used to assess the impact of a
pharmacological intervention on EF. In a sample of individuals with ADHD,
improvements in performance on a task of inhibitory control (go/no-go task) following
methylphenidate administration was associated with increased right lateral PFC
activation (Monden et al., 2012). EFs and PFC function have been examined in SUD
samples using fNIRS, as well (Monden et al., 2015).
Prefrontal Cortex and Substance Use
fNIRS has been used to detect clinically meaningful differences among
individuals with SUD. In particular, differences in PFC activation patterns in individuals
with SUD have been linked to reward processing. For instance, when exposed to drug
cues, individuals with SUD often exhibit greater PFC activation suggesting increased
effort needed to respond to cues. For instance, individuals with alcohol dependence
demonstrated increased activation in the left anterior lateral orbitofrontal (OFC) and
middle OFC when responding to alcohol cues (Ernst et al., 2014). Craving, an indicator
of SUD severity, was found to be associated with different PFC activation patterns when
viewing drug cues. More specifically, in adult smokers increased self-reported craving at
baseline was correlated with increased activation in the OFC and less activation in the left
DLPFC during smoking cue exposure (Kroczek, Haeussinger, Fallgatter, Batra, & Ehlis,
2015). When viewing non-drug related reward cues, however, individuals with SUD
exhibit a different pattern of activation. For instance, individuals receiving treatment for
opioid dependence exhibited decreased left ventrolateral prefrontal cortex (VLPFC)
activation to images of positive social interactions and decreased activation in left rostral
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PFC/VLPFC, right VLPFC, and left medial rostral PFC in response to appetitive food
cues (Huhn et al., 2016). Overall, this suggests within individuals with SUD, different
PFC activation patterns are observed when viewing of reward cues relative to controls.
Changes in PFC function while viewing reward cues has been associated with
markers of treatment success. For instance, greater right DLPFC activation to a drug cue
was observed in recently detoxified individuals with opioid use disorder compared to
individuals that underwent opioid detoxification several months earlier(Bunce et al.,
2015). Similarly, within individuals with a history of alcohol dependence, when viewing
an alcohol cue, decreased activation in DLPFC and dmPFC was associated with
increased days of abstinence (Dempsey et al., 2015). Lastly, length of recovery was
positively correlated with increased oxygenated hemoglobin concentration in the PFC
among the abstinent group during a fluency task (Dresler et al., 2012). In summary, PFC
activation during reward processing may be an important marker of SUD and a potential
biomarker of treatment success.
Executive Function: Treatment Target for Substance Use Disorder
Among adults with a SUD, however, EF is one of the best predictors of relapse.
Impairments in cognitive inhibition of prepotent responses, and other related executive
deficits, can lead to lack of control over drug or alcohol use, heightened severity of
dependence, and poor treatment response (Goudriaan, Grekin, & Sher, 2011; Miller,
1991; Poling, Kosten, & Sofuoglu, 2007). Among adults with a SUD, those with
evidence of impaired hot EF, such as increased negative affect (Miller, 1991) and
affective instability (Nace, Saxon, & Shore, 1986) have increased craving, increased
SUD severity, and poorer treatment outcomes (H. C. Fox, Bergquist, Hong, & Sinha,
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2007; Sinha, 2007). Among adolescents, hot EF deficits predict escalated drinking
patterns and binge drinking, suggesting substances may be used in an attempt to modulate
negative emotions (Colder, Campbell, Ruel, Richardson, & Flay, 2002). Likewise,
adolescents are at increased risk for developing a SUD if they exhibit impaired EF (Dom,
De Wilde, Hulstijn, van den Brink, & Sabbe, 2006; Perry et al., 2011; Squeglia, Jacobus,
& Tapert, 2009; Wilcox, Dekonenko, Mayer, Bogenschutz, & Turner, 2014) with earlier
onset of substance use linked to greater EF impairments(Sagar et al., 2015).
A recent meta-analysis examined the neuropsychological impairments associated
with OUD across 14 different cognitive domains (Wollman et al., 2019). The authors
reported the largest effect size difference (Hedges’ g = 0.970) across studies was for
complex psychomotor ability, which included Digit Symbol Substitution Test and
Symbol Digit Modality Test. Further, length of time abstinent was correlated with a
reduction in the effect size for complex psychomotor ability. However, the authors
reported the average raw score for individuals with an OUD were within the normal
range. Additionally, in follow up meta-regression analysis, attention (Trails A time)
statistically predicted effect sizes for executive function (verbal fluency, inhibition,
working memory), and verbal memory. Among individuals with OUD, differences in
delay-discounting were observed among individuals that use heroin relative to individuals
that use prescription opioids (Karakula et al., 2016).
EF task performance has been linked to changes in PFC activation among
individuals with SUD. For instance, compared to healthy controls, individuals with
alcohol dependence exhibited impaired performance on a fluency task and smaller
functional activation (oxygenated hemoglobin concentration) in regions of the PFC
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during the task (Dresler et al., 2012). In a different SUD sample, while performance on a
fluency task was comparable between an Alcohol Use Disorder (AUD) group and healthy
control (HC) group, the AUD group exhibited less of an increase in oxygenated
hemoglobin in the PFC relative to the control group (Schecklmann et al., 2007).
Differences in neural activation on tasks of hot EF have been observed in SUD as well.
For example, on the Iowa Gambling task, individuals with polysubstance use exhibited
decreased bilateral DLPFC activation compared to healthy controls (Hammers & Suhr,
2010). A few studies have reported increased PFC activity in the absence of performance
differences in individuals with SUD compared to HC. This effect, may, in part, be related
to the substance of abuse. Specifically, in studies that included ecstasy use increased
oxygenated hemoglobin in PFC areas was observed during inhibitory control and fluency
(Roberts & Montgomery, 2015). In sum, while several fNIRS studies have shown SUD is
associated with reduced PFC activation during EF tasks, this may be moderated by
substance of abuse.
Reduced PFC activation during EF has also been shown to predict future
substance use using a correlated methodology, fMRI. For instance, adolescents that later
went on to use substances exhibited less activation in the ventromedial prefrontal cortex
(vmPFC) during an inhibitory control task compared to adolescents that did not initiate
substance use(Mahmood et al., 2013). Likewise, reduced activation in the prefrontal
cortex during inhibitory control was also associated with later substance use initiation
among adolescents (Norman et al., 2011). Further, severity of future substance use
(positive history of black outs associated with drinking) was positively associated with
reduced activation in prefrontal regions during inhibitory control trials as well(Wetherill,
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Castro, Squeglia, & Tapert, 2013). Finally, improvements in emotional reactivity
following a period of abstinence have been observed among adolescents with a SUD,
suggesting hot EF improvements are associated with recovery as well (Winward,
Bekman, Hanson, Lejuez, & Brown, 2014). Reduced PFC activation during EF is
observed in adults with SUD, in adolescents that later develop SUD, and is associated
with SUD severity among adolescents, suggesting it may be an appropriate target.
Brain Function During Resting State and Substance Use Disorder
Resting state fMRI data provide support to suggest functional connectivity is
altered in individuals with SUD. Graph theory analyses have been used to identify
topological properties of networks associated with clinical variables. For instance, small
world networks properties have been observed among individuals with SUD that are both
less efficient and more connected compared to healthy controls (Wang et al., 2015).
Another study found, relative to controls, individuals with SUD showed increased global
efficiency and decreased local efficiency (Regner et al., 2016).
Resting state fMRI data also suggest reduced PFC function during resting state is
associated with SUD, as well. Adolescents with a SUD exhibit less activation in
prefrontal regions of the brain during resting state, including: superior frontal gyri,
middle frontal gyri, and medial frontal gyri compared to typically developing controls
(Dalwani et al., 2014). Adolescents that currently used alcohol and adolescents that
would later go on to use alcohol both showed increased BOLD signal in the frontal cortex
(among other regions), relative to adolescents that did not use alcohol (Ramage, Lin,
Olvera, Fox, & Williamson, 2015). Finally, among adolescents with a SUD, abstinence
from substance use was associated with greater activation in prefrontal regions at rest
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(Dalwani et al., 2014). Overall, reduced PFC activation during rest is observed in adults
with SUD, in adolescents that later develop SUD, and is associated with SUD abstinence
among adolescents, suggesting it may be an appropriate target. While there are other
cognitive deficits associated with OUD, the EF deficits are related to clinical issues
directly and are the most appropriate target.
Reduced within-PFC connectivity during rest may also be an important treatment
target. Reductions in within-PFC functional connectivity (N. Ma et al., 2010; MullerOehring, Jung, Pfefferbaum, Sullivan, & Schulte, 2015) and structural connectivity
(Huang et al., 2013; W. C. Lin et al., 2012; X. Ma et al., 2015), are both associated with
poorer EF, have been observed in adults with a SUD compared to healthy controls and
are associated with higher addiction severity, indicating a possible treatment target.
Reduced with matter integrity in tracts connecting PFC regions with one another are
observed in individuals with SUD compared to controls (De Bellis et al., 2008; Jacobus,
Squeglia, Bava, & Tapert, 2013; McQueeny et al., 2009) (F. Lin et al., 2012) and
increasing behavioral EF impairments was associated with decreasing within-PFC
structural connectivity. Overall, reduced within-PFC connectivity during rest is observed
in individuals with SUD and is associated with EF in SUD, suggesting it also may be an
appropriate target.
MBIs and Improved Executive Function
Improvements in performance on neuropsychological tests of EF have been
observed following a MBI across a range of populations. In healthy adult samples,
improvements in cool EFs, including sustained attention, inhibitory control, working
memory, and fluency have been observed after a MBI (Chambers, Lo, & Allen, 2008;
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Deepeshwar, Vinchurkar, Visweswaraiah, & Nagendra, 2014; Heeren, Van Broeck, &
Philippot, 2009; Jha, Stanley, Kiyonaga, Wong, & Gelfand, 2010; Moore & Malinowski,
2009; Mrazek, Franklin, Phillips, Baird, & Schooler, 2013; Slagter et al., 2007; Tang et
al., 2007; Vega et al., 2014; Zeidan, Johnson, Diamond, David, & Goolkasian, 2010).
Improvements on tasks of hot EF have been observed in healthy adults following a MBI
as well, including: affective Stroop, emotional attention network test, and Iowa Gambling
Task (Ainsworth, Eddershaw, Meron, Baldwin, & Garner, 2013; Alfonso et al., 2011;
Allen et al., 2012; Ortner, Kilner, & Zelazo, 2007). MBIs have been shown to improve
performance on hot EF tasks in clinical samples as well (Alfonso et al., 2011; Allen et al.,
2012). In clinical adolescent samples, improvements in cool EFs, including: sustained
attention, inhibitory control, task switching, and self-reported EF behaviors (Bogels,
Hoogstad, van Dun, de Schutter, & Restifo, 2008; Himelstein, 2011; Le & Proulx, 2015;
Leonard et al., 2013), and hot EFs have been observed (Leonard et al., 2013). The
persistence of EF gains following MBIs are still being explored and longitudinal studies
are needed. While there is evidence supporting a dose-response to mindfulness, it is
unclear how long these changes persist in the absence of continued practice.
Further, preliminary results suggest MBI may be helpful for adolescents and
adults with ADHD (a neuropsychological disorder partly characterized by EF deficits) as
evidenced by improved measures of EF (Zylowska et al., 2008) and behavior (Haydicky,
Wiener, Badali, Milligan, & Ducharme, 2012). Improvements in symptoms of inattention
and hyperactivity have been observed among individuals with ADHD following MBI
(Bogels et al., 2008; Bueno et al., 2015; van de Weijer-Bergsma, Formsma, de Bruin, &
Bogels, 2012; Zylowska et al., 2008). Among adolescents with ADHD, improvements in
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both self-reported and parent-reported symptoms of ADHD (including EF) were observed
(van de Weijer-Bergsma et al., 2012; Zylowska et al., 2008). Among adults with ADHD,
improvements in self-reported clinical symptoms of ADHD and EF were found
(Zylowska et al., 2008). In summary, MBI show promise in the treatment of a disorder of
EF in both adult and adolescent samples.
MBIs and Changes in Prefrontal Cortex Activity
There is preliminary evidence to suggest MBIs may change the pattern of neural
activation during EF tasks. The improvements in cognitive control associated with a MBI
have been associated with changes in neural processing in the right prefrontal cortex
(Deepeshwar et al., 2014). Within a sample of older healthy adults, improvements in EF
were observed that were associated changes in activation patterns using a different
neuroimaging technique, EEG. More specifically, greater right frontal alpha activation
was observed (Moynihan et al., 2013). Specific to Hot EFs, increased activation of the
DLPFC was observed during a task of Hot EF (affective Stroop task) (Allen et al., 2012).
Further, amount of meditation was positively correlated with activation in regions
including the DLPFC and medial PFC during a Hot EF task (Allen et al., 2012). Lastly,
within a clinical sample, following a MBI individuals exhibited greater activation in the
ventrolateral PFC when processing emotions (Holzel et al., 2013). However, among
healthy individuals reduced reactivity to sadness following a MBI was associated with
increased activation in regions of the ACC, vmPFC, and right superior frontal gyrus
(Farb et al., 2010). During resting state, greater activation in the left PFC were observed
in healthy adults following a MBI(Tang et al., 2009). Though preliminary, these results
provide support for the idea that MBIs alter the way the brain processes emotional states.
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More specifically, reductions in emotional reactivity may be related to changes in PFC
recruitment during processing of emotions. As mentioned earlier, while there is support
for a dose response to mindfulness, the persistence of changes in the absence of
continued mindfulness practice is unknown.
MBIs and Changes in Prefrontal Cortex Structure
MBIs have been shown to impact the structure and function of the prefrontal
cortex, a region of the brain associated with EFs (Funahashi & Andreau, 2013). For
instance, in a sample of healthy adults, increased cortical thickness in a cluster that
included the right inferior frontal gyrus was observed following an eight-week
Mindfulness-Based Stress Reduction intervention (MBSR) (Santarnecchi et al., 2014).
Further, increased white matter integrity was observed in the anterior cingulate cortex
(ACC) (Tang et al., 2010). Specific to functional changes, two studies found increased
activity in the prefrontal cortex (Davidson et al., 2003; Tang et al., 2009), while a third
study reported decreased activity following a MBI in bilateral frontal pole of the brain
(Chen et al., 2015). Each of these studies utilized a different imaging/analysis technique
and a different MBI. Consequently, while it is difficult to make a precise hypothesis
based on these findings, these results do suggest effects in the prefrontal cortex across
studies.
MBIs have been associated with increased recruitment of regions of the prefrontal
cortex based on functional and structural connectivity. Improved efficiency within the
anterior cingulate cortex (ACC) during resting state was observed following a MBI (Xue,
Tang, & Posner, 2011). Following a MBI, healthy adults experiencing unemployment
demonstrated increased functional connectivity between the left DLPFC and a seed

25
within the DMN, the posterior cingulate cortex(Creswell et al., 2016). Increased rsFC
between the between the DLPFC and the dACC was observed following a MBI(Chen et
al., 2015). Similarly, within a clinical sample, increased functional connectivity between
the PCC and bilateral medial PFC was observed following a MBI(Wells et al., 2013).
Interestingly, greater within PFC functional connectivity (increased fc between right
dorsomedial PFC to left lateral OFC) was observed in the clinical group but not the
healthy sample of individuals receiving a MBI, suggesting MBIs may impact functional
connectivity differently in clinical samples(Chen et al., 2015).
Changes within PFC functional connectivity are supported by changes in white
matter within the PFC observed following a MBI. More specifically, increased white
matter integrity was observed in in white matter tracts that connect different regions of
the PFC and within white matter tracts that connect the PFC inter-hemispherically (Tang,
Lu, Fan, Yang, & Posner, 2012; Tang et al., 2010). In sum, MBIs have been associated
with increased recruitment of PFC at rest based on connectivity measures and increased
PFC activation during EF. Overall, MBI may improve EF in substance users by
improving measures of EF and via neurobiological changes within the PFC.
MBIs and Culture
Despite the profound benefits of mindfulness practices on various facets of health,
including SUD it is important to consider the applicability of a MBI for individuals from
marginalized populations. The use of mindfulness-based interventions in marginalized
populations has become a focus in recent years. A recent study examined self-reported
engagement in mindfulness related practices and identified potential socio-demographic
barriers that are worthy of further consideration (Olano et al., 2015). Having more than a
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high school diploma was associated with increased use of mindfulness practices. Further,
non-Hispanic whites were more likely to engage in mindfulness practices compared to
Hispanic and non-Hispanic Black respondents. Further, men were less likely to utilize
mindfulness practices relative to women.
Similarly, there is research that suggests among the more common mindfulness
interventions, MBSR and MBCT, the vast majority of randomized clinical trials have
samples that are predominantly white (Waldron, Hong, Moskowitz, & Burnett-Zeigler,
2018). The authors found only one study specifically targeting a MBI among ethnic/racial
minority or lower SES samples and that study did not report findings. When examining
research studies that reported findings for other ethnic groups, 76% of the participants
reported on were white. Further, across studies, individuals had a higher education than
the normal population and more than 50% of samples reporting employment status and
mean income of $40,000 or greater. Notably, this review did not include MBRP, which
has more support for use in underserved communities.
Preliminary research supports the use of MBRP in ethnic minority populations. In
a sample of women receiving court referred residential treatment for substance use,
MBRP was found to be more efficacious than relapse prevention (Witkiewitz, Greenfield
& Bowen, 2013). Further, the role of racial/ethnic composition may moderate impact of
MBRP on specific treatment outcome variables. In particular, MBRP may be more
effective than RP for preventing heavy drinking days among whites, while among
racial/ethnic minorities, MBRP may be more effective than RP in preventing drug use
days (Greenfield et al., 2018).
Specific Aims and Hypotheses
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The primary aim of the study was to assess the feasibility of implementing a
MBRP within an outpatient substance use and methadone clinic from a
neuropsychological framework. As mentioned earlier, a neuropsychological framework
to mental health can help identify new treatment targets and assess changes in those
markers over time through the use of neuropsychological assessments, neuroimaging
methods and self-reported symptoms. Clinical neuropsychology consistently addresses
cognitive problems and in conjunction with psychological problems. SUD, and OUD in
particular, can be conceptualized as disorders of EF. Given the rates of substance use and
mental health problems during adolescence in individuals that later go on to develop
SUDs behavioral interventions that are able to simultaneously treat substance use,
comorbid psychopathology and EF are needed. MBRP is a MBI with the potential to
target each of these clinical concerns.
Overarching Aim. The current study was a pilot randomized control trial to
assess the feasibility of implementing a MBRP in an outpatient substance use clinic,
serving predominantly individuals receiving ORT. Treatment targets and study design
utilized a neuropsychologically-informed framework. The study aimed to recruit both
adolescent and young adult participants.
Specific Aim 1. Assess the feasibility of implementing a MBRP intervention
study at an outpatient substance abuse treatment clinic providing opioid replacement
therapy for adolescents and young adults. Examine participation interest and retention
rates across study and feasibility of study design, including data collection procedures
and outcome measures. Exploratory Aim: No hypothesis.
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Specific Aim 2. Examine clinical characteristics of resulting sample at baseline
and identify potential relationship between baseline factors and retention. Hypothesis 1a:
Individuals enrolled in the study will demonstrate elevated levels of psychopathology and
substance use. Hypothesis 1b: Individuals retained will demonstrate less psychopathology
at baseline relative to individuals that were lost to follow up.
Specific Aim 3. Assess EF at baseline and the relationship among specific EF
measures. Hypothesis 2a: Individuals will demonstrate impaired EF at baseline compared
to the population mean. Hypothesis 2b: EF measures will be correlated, with higher
correlations among neuropsychological measures of EF relative to self-reported measures
of EF.
Specific Aim 4. Assess topological properties of fNIRS resting state networks and
relationship to baseline measures of EF. Hypothesis 3a: Resting state networks will
exhibit small world properties. Hypothesis 3b: Performance on neuropsychological
measures of EF will be associated with small world network parameters.
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METHODS
Experimental Design
The study used a single-site, randomized waitlist control study to assess the
effectiveness of Mindfulness Based Relapse Prevention (MBRP) in adolescents and
young adults diagnosed with a SUD. Potential participants were recruited from the
adolescent and young adult clinic at the Addiction and Substance Abuse Program
(ASAP) at the University of New Mexico.
All existing clients expected to continue in treatment for at least another 8 weeks,
and newly enrolled clients thereafter (ages 14-34) were informed about the study.
Interested participants were given a copy of the study consent form and a study flyer with
contact information. Adolescents were encouraged to take the consent form home and
talk to family members before signing it. All young adult participants (age 18-34) were
randomized to receive: 1) MBRP, or 2) Waitlist Control and were not blinded to group
assignment. Participants in the MBRP group received a 4-week MBRP treatment.
Participants in the WC received treatment as usual during that time. Both groups
completed one follow up visit following completion of treatment phase. The WC group
was offered the MBI after all assessments had been completed.
Recruitment Procedures
Potential participants were recruited from the adolescent and young adult clinic at
the Addiction and Substance Abuse Program (ASAP) at the University of New Mexico.
The adolescent clinic at ASAP opened in October 2015 and at the time of our initial
submission had 30 clients enrolled, ages 14-22 years, meeting criteria for opioid use
disorder, alcohol use disorder, cocaine use disorder, cannabis use disorder, and
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polysubstance use disorder. 2-4 clients per week are screened. The clinic reports 85% of
the patients in the adolescent clinic have been retained in their program for 8 weeks or
longer. At the time of our submission, the clinic reported 70% of the treatment population
is receiving Opioid Replacement Therapy (ORT) with the 30% on additional
psychotropic medications. Per director’s report, adolescents are excluded if a residential
or higher level of care is warranted based on screening visit at the clinic (i.e., active
severe suicidal/homicidal ideation, active severe behavioral/aggression issues). Typical
co-occurring disorders observed at this clinic include: posttraumatic stress disorder,
major depressive disorder, pervasive developmental disorder, generalized anxiety
disorder, and panic disorder.
In May 2018 the study team was made aware of changes to the clinic that
impacted recruitment. The clinical director of ASAP, Larissa Maley, Ph.D., provided the
study team an update on recent structural changes within ASAP. Per director report,
adolescents ages 14 to 17 years of age receive treatment within the adolescent clinic at
ASAP, while young adults, ages 18 years and older receive treatment in the adult clinic at
ASAP. This decision was made based upon the clinical needs of the population served
within ASAP. Additionally, per clinic director’s report, the clinic has received an influx
of individuals under 18 years of age with severe psychopathology that would likely result
in them being excluded from this study. Consequently, based on these updates to the
clinic, the clinical recommendations of providers at ASAP, and a reduction in the size of
the recruitment pool within this age range, adolescents between the ages of 14 and 17
years interested in participation will be consented and enrolled in an Under 18 MBRP
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group. They will not be randomized to the waitlist control condition, because it was
deemed unlikely there would be sufficient sample size to achieve this.
Additional inclusion criteria include: current diagnosis of SUD based on the
Structured Clinical Interview for DSM-V (SCID). Additional exclusion criteria include:
1) significant impairment of cognition or judgment (as observed by study staff or
indicated by chart review) rendering the person incapable of informed consent, 2) brain
injury with loss of consciousness greater than 30 minutes based on Center for Disease
Control’s definition of moderate to severe TBI, 3) diagnosis of epilepsy (based on chart
review), 4) active psychosis (determined by both chart review and SCID). Participants
currently taking prescribed psychoactive medications were not excluded, however,
participants were stabilized on psychiatric medication, including ORT, prior to
enrollment in the study.
Study Intervention and Assessment Procedures
The assessment battery (EF, ER, and substance use assessments) were completed
at baseline and at a follow up visit (following completion of treatment) by trained
research assistants in quiet rooms designed for testing. The assessment battery took
approximately 3 hours. Transportation was provided to transport participants between
ASAP and Center for Psychiatry Research/MRN as needed. As mentioned earlier,
participants underwent a 30-minute fNIRS scan visit at baseline and at follow up. The
participant was seated at a desk and the cap of the fNIRS acquisition device was placed
on the participant’s head. After 2-3 minutes for equipment checks, the experimenter
administered a seven-minute resting state task.
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MBRP. Participants received a condensed version of Mindfulness-Based Relapse
Prevention an intervention that integrates cognitive-behavioral relapse prevention and
mindfulness practices (Bowen et al., 2011; Roos, 2019). The study intervention was
provided over the course of eight bi-weekly sessions (60 minutes each) and followed the
procedures outlined in the treatment manual(Bowen et al., 2011; Roos, 2019). In each
session participants were instructed on specific mindfulness practices (e.g. body scan,
mindful movements) and ways to use these practices during high-risk situations (i.e.
situations that trigger substance use). Participants were assigned to practice mindfulness
activities at home between group therapy sessions. All MBRP sessions were provided at
ASAP in rooms designed for group therapy.
Therapist Qualifications, Training, and Supervision. Therapists had at least a
master’s degree in a related field with clinical experience working with pediatric and
adult samples. Consistent with prior MBRP studies, therapists were required to read the
entire therapy manual, attend a basic training in MBRP, and commit to a personal daily
mindfulness practice (Bowen et al., 2011). Cases were discussed in weekly group
supervision.
Assessments
Neuropsychological Measures of EF. Subtests were selected from two different
assessment batteries: the Delis-Kaplan Executive Function System (D-KEFS) and the
National Institute of Health (NIH) Toolbox for the Assessment of Neurological and
Behavioral Function (NIH-TB).
The Delis-Kaplan Executive Function System (D-KEFS) is a widely used battery
of EF tests (Delis, Kaplan, & Kramer, 2001). The D-KEFS was normed on a sample of
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1,700 children and adults (age 8-89 years) with demographic characteristic consistent
with the United States population according to the 2000 US census. In particular, the trail
making test (TMT), Color word Interference and Verbal Fluency tasks are frequently
used. The TMT was designed to measure different cognitive skills that contribute to
performance on the more widely known Trail Making Testing with two conditions. TMT
consists of five conditions that measure, visual scanning, number sequencing, numberletter switching, and motor speed, respectively. Verbal Fluency measures fluent
productivity in the verbal domain across three conditions. On the first condition, the
individual is asked to say names beginning with a specific letter (Letter Fluency), on the
second condition the individual is asked to name words from a specific category
(Category Fluency), and on the third condition the individual is asked to switch between
saying words from two different categories (Category Switching). Two scores are
produced from this condition: total number of words and accuracy in switching. ColorWord Interference is similar to the Stroop test. The individual is asked to name color
patches in condition 1, read the color names printed in black ink on the second condition,
and then on condition 3, the participant must name the color of the ink that color words
are printed in (e.g., the individual must say “red” when reading the word “blue” which is
printed in red ink). The fourth condition adds a switching condition, where the individual
is instructed to shift back and forth between naming the ink colors and reading the color
words. Internal consistency across the select subtests varies. Internal consistency from
TMT for combined number and letter sequencing composite ranges from .60 to .81 .
Verbal fluency internal consistencies by condition: Letter Fluency .68-.90, Category
Fluency .53 to .76, Switching Total Correct .37 to .68, and Switching Accuracy .51 to
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.76. Internal consistency for Color Word Interference for combined color naming and
word reading composite score ranges from .62 to .86. Correlations between tasks on the
D-KEFS are relatively low, while correlations among measures from the same task are
higher.
The National Institute of Health (NIH) Toolbox for the Assessment of
Neurological and Behavioral Function (NIH-TB) was developed to measure four
domains: cognition, motor function, sensation and emotion (Weintraub et al., 2013;
Weintraub et al., 2014). Specific to the Cognition Domain, the toolbox includes several
tests of EF that can be used to measure the construct across the lifespan at multiple time
points. The Cognition Battery covers seven cognitive subdomains, defined by the creators
as: Executive Function, Episodic Memory, Language, Processing Speed, Working
Memory and Attention. The tasks were normed on a sample of 476 individuals ages 3 to
85 years. Three levels of education and 3 racial/ethnic categories were included. The
Toolbox contains four measures of EF that map well onto Miyake and Friedman’s model
of EF.
The NIH-TB Flanker Inhibitory Control and Attention Task is a variant of the
Eriksen flanker task used on the Attention Network Test. On each trial, the individual is
presented with an arrow in the center of the screen, flanked by similar arrows on either
side of it. On congruent trials, the center arrow and the flankers are pointing in the same
direction. On incongruent trials, the flankers are pointing in the opposite direction as the
center arrow. The participant must respond to indicate the direction of the center arrow as
quickly as possible. This task measures one’s ability to inhibit attention to visual
distractors. This task takes approximately 4 minutes to complete and consists of 40 trials.
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The NIH-TB Dimensional Card Sort Test measures shifting ability. Individuals
are presented with a target image and then asked to match it to one of two stimuli based
on either shape or color. The word “color” or “shape” appears on the screen to indicate
which category to use. This task takes approximately 4 minutes to complete and consists
of 40 trials.
The NIH-TB List Sorting Working Memory Test was adapted from the Mungas’
List Sorting task. Participants are presented with a series of stimuli visually and orally,
one at a time. In the first condition, participants must then repeat back the items in order
of smallest to largest. While all the stimuli are from the same category in the first
condition, in the second condition, participants are given stimuli from two different
categories. They are then asked to repeat back the items from smallest to biggest for the
first category and then the second category. The number of stimuli presented increases
across trials. The test is discontinued when an individual fails two trials of the same
length. This test takes approximately 7 minutes to administer. The NIH-TB Pattern
Comparison Processing Speed Test is based on the Salthouse’ Pattern Comparison Task.
On this task, participants are asked to pick if two images or patterns are the same or
different. This task takes approximately 3 minutes to administer and the score is the total
number of correct items (up to 130) finished in 90 seconds.
Self-Report Measures of EF. Barrett Impulsiveness Scale (BIS-11) is a 30-item
self-report measure of impulsivity. Internal consistency coefficients range from .79 in a
sample of patients receiving treatment for substance use to .82 for undergraduates and .83
for psychiatric samples (Patton, Stanford & Barratt, 1995). White Bear Suppression
Inventory (Wegner & Zanakos, 1994) is a 15-item questionnaire measure of thought
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suppression. Internal consistency coefficients ranged from .87 to .89 and reliability
ranged from .92 to .69. The Difficulties in Emotion Regulation (DERS) is a 36-item selfreport measure of self-reported emotion regulation problems (Gratz & Roemer, 2004).
Internal consistency ranged from .82 to .94 (Hallion, Steinman, Tolin, & Diefenbach,
2018).
Mood and Anxiety Measures. Perceived Stress Scale (PSS) is a 10-item scale
that measures the extent to which events in one’s life are perceived as stressful. Internal
consistency ranged from .84 to .86 and test-retest reliability ranged from .55 to .85
(Cohen, Kamarck, & Mermelstein, 1983). The Penn State Worry Questionnaire (PSWQ)
is a 16-item measure of frequency and intensity of worry (Meyer, Miller, Metzger, &
Borkovec, 1990). It has good internal consistency (.88 to .95) and good test-retest
reliability (.92). The Beck Depression Index-Two (BDI-2) is a 21-item self-report
measure of presence and severity of symptoms of depression. It takes approximately 10
minutes to complete. Internal consistency coefficients range from .73 to .92 and internal
consistency (alpha coefficients from .86 to .81) (Beck, 1988). State Trait Anxiety Index
(STAI) is a 40-item questionnaire that assess both state anxiety and trait anxiety
symptoms (Spielberger, 1983). Internal consistency coefficients range from .86 to .95,
with test-retest reliability coefficients from .65 to .75 (Spielberger, Gorsuch, Lushene,
Vagg, & Jacobs, 1983).
Substance Use Measures. The Form 90 is a semi-structured interview that
captures substance use and treatment use in the past 90 days. The Alcohol & Drug
Consequences Questionnaire is a 28-item questionnaire created to capture motivations to
make changes in substance use behaviors and motivations to stay the same. A Visual
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Analogue Scale for craving was administered where individuals mark on a 100millimeter line the extent of craving they feel at that moment for the drug of abuse,
ranging from 0 to 100.
Mindfulness Measures. Mindful Attention Awareness Scale (MAAS) is a 15item questionnaire created to measure receptive a core component of trait mindfulness:
the awareness and attention to present moment experience. Internal consistency was .89
(MacKillop & Anderson, 2007). The Kentucky Inventory of Mindfulness Skills (KIMS)
is a 39-item questionnaire that assesses four mindfulness skills: observing, describing,
acting with awareness, and accepting without judgment (Baer, Smith, & Allen, 2004).
Internal consistency coefficients range from .76 to .91 and test-retest reliability ranges
from .65 to .86.
Additional Measures. Substance Use and Psychotic and Associated Symptoms
sections of the Structured Clinical Interview for DSM-V (SCID), CASAA Demographic
Questionnaire, and an experimental hot EF task, an emotional go-no-go task were
administered. Specific to the hot EF task, on each trial participants’ were presented with
one of two shapes (circle or square) and instructed to only respond (i.e., hit the space bar
on a laptop) when they saw one of the two shapes. Participants were presented with
neutral or distressing images in between each trial.
Neuroimaging Acquisition and Analyses
NIRS data was collected using the NIRScoutX 64x32 imager system produced by
NIRSX Medical Technologies, LLC. A sampling rate of 2.60 was utilized based upon the
number of channels. A NIRX cap was utilized and a user-defined montage was designed
based on previous studies examining whole-head resting state scans using NIRS (Geng,
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Liu, Biswal, & Niu, 2017; Novi, Rodrigues, & Mesquita, 2016). The montage was
comprised of 46 optodes: 22 source optodes and 23 detector optodes, for a total of 80
identified potential channels out of 552 possible channels. The montage created was
intended to capture cortical activity in frontal, occipital, temporal and parietal cortices. 24
channels covered the frontal lobes. The EEG 10-20 coordination system was used to
support accurate placement of optodes. Per NIRX instructions, all caps placed on
participants’ heads were aligned with the CZ point as measured on each individual
(measure inium to nasium).
Raw data was converted to nirs format using a modified version of the NIRx2nirs
script running in matlab that utilizes functions from Homer2 toolbox for nirs analysis
preprocessing. Data preprocessing involved 3 steps to reduce the “noise” in the data:
truncate the time series to select appropriate time intervals, removal of data artifacts, i.e.,
“steps” and “spikes”, and filter frequency bands that are irrelevant to the data. Several
different frequency bands are available for use. A low pass frequency filter removes all
data above a predefined threshold or time scale, and is often used to de-noise the data. A
high pass frequency filter is used to de-trend the data. For the present analyses, a band
pass filter was selected as it serves to filter out both high and low frequency data and is a
combination of the high and low pass filters. Parameters for Hb-concentration
calculations were selected and used to compute the hemodynamic states making use of
the Beer-Lambert Law.
Preprocessing was completed using the FC-NIRS toolbox. All raw data went
through the following processes: Intensity2OD, OD_bandpassFilter, OD2Con, Detrend,
MotionCorrect_Spline, and MotionCorrect_CBSI. Cut time was the only step removed
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from the default setting and the two motion correction methods were added: a spline
interpolation method and a correlation-based signal improvement (CBSI) approach.
Resting-State Task. Prior to initiation of the task, participant were told they
would be asked to sit quietly for eight minutes with their eyes closed. They were
instructed to do their best not to move during the task. Following a 30 second baseline,
participants were then instructed to “close your eyes, think about nothing in particular”.
Functional Connectivity Analysis. Functional connectivity was calculated first
using the whole-brain correlation approach. Relative to a seed-based approach, the whole
brain approach to connectivity calculates the strength of the correlation between brain
regions. Pearson correlations between channels were generated. Graph metrics were
generated using FC-NIRS toolbox, which utilizes the Gretna toolbox. The Gretna toolbox
uses scripts and functions from the Brain Connectivity Toolbox (BCT). BCT is a matlab
toolbox that analyzes complex brain connectivity networks using graph theory. The
methods in BCT have been applied to both structural and functional connectivity analyses
across a range of different imaging methods including fMRI, DTI, and EEG. When
applying graph metrics to fnirs data, each channel is a vertice and the connectivity
between two channels is an edge(Xu et al., 2015). The FC-NIRS toolbox performs graph
analyses on the HbO, HbR and HbT maps separately.
Global and nodal topological features of the network are calculated via the FCNIRS toolbox and compared to random networks (Wang et al., 2015). Gretna uses the
Markov-chain algorithm to generate random networks. Using this approach, random
networks were generated (1000) with the same number of nodes, edges, and degree
distribution. Binary networks were examined using a sparsity threshold (0.1 to 0.5 with
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0.01 intervals). Five small world properties were calculated (clustering coefficient, path
length, gamma, lambda, and sigma), two measures of efficiency (global and local
efficiency), and one nodal measure (degree centrality) were calculated. The Area under
the curve (AUC) was for network measures as well.
Small worldness was measured using five different, but related variables. The
clustering coefficient of the network (Cp) and the shortest path length of the network (Lp)
were generated for each participant and at the group level. Gamma was calculated, which
is the ratio of Cp and the mean value of Cp from the random network. Lambda is the ratio
of Lp and the mean value of Lp from the randomized network. Sigma is the ratio of
Gamma and Lambda. The Area Under the Curve (AUC) was generated for Cp and Lp to
get a scalar variable for these variables that is not impacted by threshold selection.
Statistical Analysis
Data analyses for specific aims 1 through 3 were conducted using IBM SPSS
Version 26. For specific Aim 4 the following programs were used: FC-NIRS toolbox and
Gretna toolbox that use scripts and functions from the Brain Connectivity Toolbox (BCT)
run in Mathworks (MATLAB 2019a).
Specific Aim 1. Retention rates and frequency analyses were performed.
Descriptive statistics were performed on baseline characteristics.
Specific Aim 2. Descriptive statistics were performed on symptom measures.
Mann-Whitney U Tests were performed to examine differences between individuals that
completed follow up relative to those that did not on 11 baseline variables. Fisher’s Exact
Tests were performed to assess differences in 7 categorical baseline variables among
individuals that completed follow up and those that did not.
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Specific Aim 3. Spearman correlation coefficients were calculated to examine
relationships between EF tests (4 scores from the NIH toolbox, 13 scores from D-KEFS,
and 3 scores from self-report measures) at baseline. Single sample T-tests were
performed to examine differences between population mean and study sample mean for
the EF scores (4 scores from the NIH toolbox, 13 scores from D-KEF).
Specific Aim 4. Functional connectivity matrices were generated for resting-state
fNIRS networks using Pearson correlation coefficient. Topological properties of resting
state networks were generated across multiple sparsity thresholds and using Area Under
the Curve scalar values. Spearman correlation coefficients were calculated to examine
relationship between 20 EF variables (17 neuropsychological scores and 3 self-report
scores) and 7 network measures.
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RESULTS

Specific Aim 1: Feasibility Assessment
Recruitment Phase. The treatment protocol was presented at staff meetings for
treatment providers in the general clinic and within the STAR program team. Based upon
recommendations from treatment staff members, participants were recruited from the
clinic on a variety of days and times. Clients at the clinic receive medication on different
schedules based upon treatment phase. Thus, while some clients present to the clinic
daily to receive medication, others are able to take home several doses at a time. With
extended compliance of treatment demands, clients may earn up to a 30-day supply of
medication to take home. Thus, recruitment efforts were coordinated to ensure the widest
net was cast within the adult clinic (age 18 and older). Based upon staff
recommendations, additional recruitment efforts were conducted in early morning hours
(6:00 am to 11:00am).
Efforts to recruit from the STAR program were similarly coordinated based upon
client flow in the clinic. Treatment staff recommended efforts to recruit from the
adolescent clinic be scheduled in afternoons. The flow of adolescent patients to the ASAP
clinic during the recruitment phase of the study (May 2018 through July 2018) were
significantly fewer than originally predicted (0 to 3 adolescents presenting to the clinic on
any given day). As previously mentioned, the psychopathology among the adolescents
was more severe than had been previously expected during initial meetings with the staff.
Flyers were also placed throughout the clinic with the study contact number.
Additionally, on recruitment days, potential participants were offered flyers and later a
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recruitment table was set up. Overall, 78 participants indicated interest in participating in
the group. Of those, at least 45 were within the targeted age range for the young adult
group. One potential participant under 18 years of age indicated interest but was unable
to attend due to transportation. Four individuals age 18 to 20 years of age indicated
interest, of those two were disqualified by ASAP staff, one declined to participate due to
scheduling conflicts and one declined to participant for personal reasons.
Qualitatively, it was noted interested participants verbally expressed interest in
the neuroimaging component of the study. Compensation was very limited and
participants interested in the treatment verbally expressed motivation based on the
treatment opportunity and research experience. Per staff and patient report, group
interventions were relatively new to the clinic, which likely impacted recruitment. Over
the course of the study increased referral from staff and referral among patients were
helpful.
Retention. Throughout the course of the study, retention was a significant
challenge. At each phase of the study participants were lost to follow up. 20 Participants,
six men and fourteen women, were consented to the study. Nine participants were
Hispanic, one participant was Native American/Alaska Native, and ten participants were
white. Participants averaged 28.90 years of age (SD = 3.26, range 23-34). Of those, 16
participants completed screening visits. One participant consented to treatment but was
excluded prior to screening visit based on ASAP staff personnel suggestion. Two
participants that consented to treatment declined scheduling a screening visit due to
schedule changes and/or personal reasons, and one participant was lost to follow-up after
the consent visit.
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During the screening process, two participants were excluded due to active and
uncontrolled psychosis, and one participant was excluded due to psychosis, severe
depression, severe suicidal ideation, and a history of aggressive behaviors associated with
psychotic episodes. 13 participants completed baseline assessment visit and were
randomized to treatment.
Treatment Exposure and Follow-Up. Six participants were randomized to
waitlist and seven participants were randomized to the intervention condition. Among
individuals randomized to receive treatment (intent to treat), 6 of the 7 attended two or
more sessions. One participant declined to participate in treatment following
randomization and received 0 sessions. Of those that attended treatment, they received an
average of 4.5 sessions of treatment. Six of the thirteen participants (3 per group)
completed the follow up visit. Please see Figure 1 for recruitment and retention outline.
There were no adverse events reported. Several participants underwent changes to
psychiatric medications during the study. Of the 13 individuals randomized to treatment,
two participants received an administrative discharge from the ASAP treatment program,
one participant discontinued services at the treatment program, and one participant was
lost to follow up by all treatment staff following a relapse. Additional issues impacting
retention: included lack of transportation to ASAP clinic, lack of stable means of
communication with study team, and scheduling conflicts associated with school/work.
This is a significant limitation of the study that will be explored further in the discussion
section.
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75 initiated screening process

20 consented
3 lost to follow up
1 excluded based
on clinical judgment
of clinic staff

16 completed screening visit
3 excluded for
psychiatric condition

13 completed baseline visit

6 received 2 MBRP or more sessions

Waitlist Group

1 declined all MBRP sessions

3 completed follow up visit

3 completed follow up visit

4 lost to follow up

3 lost to follow up

Figure 1. Flowchart for study recruitment and retention. MBRP, Mindfulness-Based
Relapse Prevention.
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Feasibility of Study Design and Procedures. Three research assistants were
trained to assist in recruitment to enable recruitment to target both the STAR clinic and
adult clinic simultaneously. Consistent research study staff presence helped address
frequent no shows. For instance, on days multiple research team members were present, it
was possible to schedule multiple potential participants or meet with “walk in”
participants. Given the culture of “walk-in” health care available at the clinic, when
possible, it was beneficial for study staff to be available to meet with walk-in study
participants or participants that wished to reschedule. Qualitatively, it was noted
potential participants at the clinic often engaged with study staff on multiple occasions
before requesting additional information about the study.
Flexibility around timing of study procedures also appeared important. For
instance, on several occasions staff members met with interested participants for the
consent visit over multiple sessions. Since there was no permanent or semi-permanent
office space consistently available within the clinic, it was important to have all materials
needed on hand for the different stages of recruitment. Notably, the baseline procedure
involved neuroimaging and neuropsychological testing equipment and was completed at
a different location. Likely, if baseline and follow up visits could have been completed at
the clinic in semi-permanent space, this might have increased follow up rates. Finally,
the intervention was successfully implemented to participants in the treatment group.
Thus it was feasible to implement an empirically supported intervention within a
methadone clinic.
Feasibility of Study Measures. Regarding measures of EF, both the
neuropsychological measures and self-report measures were successfully administered.
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The experimental hot EF task was administered to a subset of the participants.
Qualitatively, the task was time consuming (approximately, 15 minute minimum). It was
the last EF task administered to prevent a carry over effect to cool EF tasks. While it was
tolerable for most participants, based on clinical judgment it was not administered to
several participants. Again, the presence of multiple study staff members significantly
expedited the set-up time need for NIRS. Similarly, on occasions when multiple
participants arrived at the clinic together, when multiple staff members were present, the
process was faster. Qualitatively, it was noted that participants expressed interest in
NIRS and all participants requested pictures or video of their brain scans. FNIRS does
enable immediate display of activation on a glass brain, which makes it a more
reinforcing experience for participants. Several analysis toolboxes have been created for
fNIRS, with varying complexity. FC-NIRS is relatively, user-friendly program with
relatively fast computation time. While some tasks could be batched during the analyses,
future efforts to batch preprocessing steps would likely speed up the analyses further.
While the GUI interface was user friendly, many of the preprocessing steps (e.g.,
calculation of Hb-concentrations, application of frequency filters, truncation of time
series) were performed for each participant separately. Thus, for each participant, the
user must manually select the input and output file locations, select the desired frequency
filters, and enter the time series to be selected. While this was quite feasible with a small
sample size, it would be more taxing with larger sample sizes. Automating this process
through scripts or via a GUI designed to run batch jobs would be helpful.
Regarding measures of mood, there was some redundancy across measures.
Elimination of some measures would likely shorten the process. Likely, one of the two
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mindfulness measures would likely be sufficient. While a heterogeneous sample in terms
of substances of abuse may reflect more “real world” clinics, often measures of substance
use and measures of SUD outcome, are designed for a single substance of abuse.
Assessment measures designed to capture multiple substance uses would likely be
helpful. Finally, measures specific to ORT would perhaps be useful. The Drug Use
Consequences form likely was not appropriate for participants at all stages of treatment
as it captures consequences and benefits for quitting rather than maintaining the current
behavior change. Measures of motivation and readiness to change might be particularly
useful for this sample. Finally, measures of functional outcome would likely be useful to
capture meaningful change in the context of ORT.
Specific Aim 2a: Clinical Characteristics of Sample
Demographics. Participants were nine women and four men with DSM-5
substance use disorder. Three participants were Hispanic, one participant was Native
American/Alaska Native, and nine participants were white Non-Hispanic. Mean age was
28.28 (SD 2.6, range 25-33). Participants averaged 12.4 years of education (SD 2.2, range
8-16). One participant reported English as a second language and three participants
reported speaking a second or third language. Three participants reported part-time
employment, nine participants were unemployed, and one participant was receiving
disability. One participant was living in his/her own apartment, one participant was living
in a transitional substance use treatment facility, and eleven participants were living with
relatives. None of the participants reported experiencing homelessness and none of the
participants reported being court-ordered to treatment.
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Baseline Characteristics. Of the 13 participants that completed the baseline
visit, nine participants presented with opioid use disorder, one participant with alcohol
use disorder, one participant with inhalant use disorder, one participant with cannabis use
disorder, and one participant with methamphetamine use disorder. All but one of the
participants was being treated with MAT. Of the 12 individuals prescribed MAT, seven
participants were prescribed methadone, three were prescribed buprenorphine, and two
were prescribed naltrexone. In total, 12 of the 13 participants reported use of two or
more substances when using their drug of choice. Nine of the 13 participants reported
concurrent abuse of opioid and stimulants.
Psychiatric History and Present Level of Care and Substance Use Treatment.
Mean number of inpatient psychiatric hospitalizations was 1.38 (range 0-6) and seven of
the 13 participants had attempted suicide one or more times (range 0-6). A significant
proportion of the sample (92%) reported one or more co-morbid psychiatric diagnoses
and nearly three quarters of the sample (76.9%) were taking one or more psychiatric
medications (range 0-5 psychiatric medications). In the 90 days prior to baseline
assessment, mean number of outpatient therapy sessions was 11.61 (range 3-28; SD =
6.55). Lastly, mean age of first psychiatric problems was 15.15 (range 10-26, SD =
5.28), mean age of first alcohol use was 15.83 years (SD = 3.29) and mean age of first
substance use was 14.84 years (SD = 2.54), while mean age of first substance use
treatment was 22.76 years of age (SD = 3.91). Please see Table 1 for additional
information on psychiatric and substance use history.
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Table 1
Sample Demographics
Variable

RTF
(n = 6)

LTF
(n = 7)

Total
(N = 13)

U

p-value

29.5 (2.95)

27.4 (2.25)

28.38 (2.69)

13

0.085

1, 5

3, 4

4, 9

-

0.559

2

1

3

-

0.559

0

1

1

4

5

9

2

2

4

-

1.0

3

4

-

1.00

7.5 (3.99)

4 (1.29)

9

.08

4

5

-

1.0

11.5 (2.81)

13.14 (1.07)

12.38 (2.14)

10

0.198

5
1
0

5
0
2

10
1
2

-

0.462

Age of First Mental
Health
Mean (SD)
Age at First Drug use
Mean (SD)

14.83
(3.66)

15.43 (6.68)

15.15 (3.3)

18.5

.720

15.83
(2.32)

14 (2.58)

14.85 (2.54)

11

.15

Age Substance use
treatment
Mean (SD)

23.17
(4.36)

22.43 (3.82)

22.77 (3.92)

20

.886

Age, years
Mean (S.D.)
Sex (M, F)
Ethnicity
Hispanic
Native American
Non-Hispanic White

Ethnic Minority Status
MBRP Group

7

Total Study Visits

Employment Status
(Number Unemployed)
Education
Living with Relatives
Transitional Living
Living Independently

5.6 (3.28)

9
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Number of Suicide
Attempts
Mean (SD)
Inpatient
Hospitalizations

2.6 (2.3)

1.17 (1.94)

1.81 (2.14)

8.5

.219

2 (2.76)

0.43 (0.53)

1.15 (1.99)

16.5

.477

Outpatient Therapy Days

11.5 (4.51)

11.71 (8.3)

11.62 (6.55)

18.5

.720

Drug of Abuse Days

0.33 (0.82)

23.71
(30.48)

12.92 (24.74)

11.5

.122

Other Drug Days

19 (35.05)

64.42
(43.67)

43.46 (44.95)

11.5

.151

Number of Psych
Medications

3.5 (1.52)

1 (1.15)

2.15 (1.82)

4

.013

0

5

5

-

.021

Discontinued at Clinic

Note: RTF, Return To Follow Up; LTF, Lost to Follow Up; M, male; F, female; S.D.,
standard deviation. Significance levels were determined by Mann-Whitney U test and
Fisher’s Exact Test.
Measurements of Substance Use. Participants reported a high level of
perceived benefit associated with changing/maintaining reduction in substance use (M =
4.47, SD = 0.58), and a relatively lower level of perceived cost associated with this
change (M = 2.36, SD = 0.73). Perception of current level of craving was also measured
using a visual analogue scale (M = 21.75, SD = 21.88). In the past 90 days, roughly one
third of participants (38%) reported use of substance of abuse (days of use: M = 12.90),
and about three quarters of the sample (76.9%) reported use of another substance of
abuse (days of use: M = 43.4). Abuse of prescription medication was reported by at least
two participants. Over half the sample (61%) reported use of marijuana at baseline.
Finally, all but one participant reported some tobacco use in the past 90 days. Please see
Tables 1 and 2 for additional information on substance use reported at baseline.
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Table 2
Baseline Self-Report Measures
Measure

TOTAL
M (SD)
19.69 (13.07)
21.92 (6.92)
57.15 (11.25)
37.67 (9.72)
46.33 (12.07)
120.38 (15.06)
3.78 (0.88)
21.75 (21.88)

RTF
M (SD)
27 (15.06)
22.83 (8.04)
61.5 (8.76)
42.8 (13.10
54 (13.27)
114.17 (17.06)
33.50 (6.12)
24.00 (24.31)

LFT
M (SD)
13.43 (7.3)
21.14 (6.36)
53.43 (12.42)
34 (4.58)
40.86 (8.11)
125.71 (11.8)
45.14 (9.77)
19.5 (21.22)

U

P

BDI-2
9
.086
PSS
14
.313
PSWQ
13
.252
STAI-S
12.5
.414
STAI-T
7
.088
KIMS-Total
12.5
.221
MAAS
6
.031
VAS Craving
15.5
.688
ADCQ
4.47 (0.58)
4.34 (0.72)
4.58 (0.46)
16.5
.517
benefits
ADCQ costs
2.36 (0.74)
2.40 (0.48)
2.33 (0.94)
16.5
.52
BIS-11
67.92 (8.89)
69.5 (10.13)
66.57 (8.24)
16.5
.52
WBSI
53.54 (7.62)
53 (9.44)
54 (6.43)
20.5
.943
DERS
94.31 (23.0)
106 (23.55)
84.2 9 (18.50)
10
.116
Note: BDI, Beck Depression Inventory; PSS, Perceived Stress Scale; PSWQ, Penn State
Worry Questionnaire; State Trait Anxiety Inventory-State, STAI-S; STAI-T, State Trait
Anxiety Inventory-Trait; KIMS-T, Kentucky Inventory of Mindfulness Skills- Total;
MAAS, Mindful Attention Awareness Scale; VAS, Visual Analogue Scale; ADCQ,
Alcohol and Drug Consequences Questionnaire; BIS, Barrett Impulsivity Scale; WBSI,
White Bear Suppression Inventory, WBSI; DERS, Difficulties in Emotion Regulation
Scale; RTF, Return To Follow Up; LTF, Lost to Follow Up; M, mean; S.D., standard
deviation. Significance levels were determined by Mann-Whitney U tests and Fisher’s
Exact Test.
Measurements of Mood, Anxiety and Mindfulness. At a group level,
participants reported elevated levels of depressed mood on the BDI-2 (M = 19.69, SD =
13), with six reporting moderate or greater depressed mood and seven reporting minimal
to mild depressed mood. Regarding anxiety, participants reported high levels of trait
worry (PSWQ: M = 57.15, SD 11.25), and elevated levels of state and trait anxiety
(STAI-T: M = 46.8, SD 12.5; STAI-S: M = 37.6, SD 9.7). Participants also reported
experiencing an elevated number of events perceived to be stressful over the past month
(PSS: M = 21.9, SD = 6.9). Regarding self-reported mindfulness, on the Mindful
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Attention Awareness Scale (MAAS) scores were comparable to that reported by a college
student sample (M = 3.78; SD = 0.87). On the KIMS Total Mindfulness score was 120.38
(SD = 15.05). Please see Table 2 for additional information on symptoms reported at
baseline.
Specific Aim 2B: Examine Correlates Between Retention and Baseline Correlates
Using Fisher’s Exact Test, follow up attendance did not differ by gender,
(p = .559); Hispanic ethnicity (p = .559); ethnic minority status (p = 1.0); employment
status, (p = 1.0). No differences in age at baseline (U = 13; p = 0.245), age at first
substance use treatment encounter (U = 20; p = 0.886), suicide attempts (U = 8.5; p =
0.219), age at first mental health encounter (U = 18.5; p = 0.720), number of inpatient
hospitalizations (U = 16.5; p = 0.477), age first drug use (U = 11; p = 0.150), number of
outpatient therapy days at baseline (U = 18.5; p = 0.720), number of days substance of
abuse was used (U = 11.5; p = 0.122), or number of days other substances used (U =
11.5; p = 0.151). Number of psychiatric medications (U = 4; p = 0.013) at baseline was
significant, with greater psychiatric medications associated with greater likelihood of
completing the follow up visit.
Consistent care within the treatment facility was an important factor. Four of the
participants lost to follow up were no longer receiving care at the facility at the time of
the follow up visit. Follow up attendance was related to continued care at the facility at
the time of the follow up visit (p = .021, Fisher’s Exact Test). Please see Table 1 and 2
for complete list of baseline variables examined and corresponding significance values.
Aim 3: Relationship Measures of EF
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Neuropsychological and Self-Report Measures of EF at Baseline. At a group
level, when compared to normative data, participants scored in the average range on all
measures of EF, with the exception of PC (M = 74.95, SD = 15.17), which was below the
general population, t(12) = -5.95, p = 0.000, 95%CIs [-34.21, -15.87]. More specifically,
participants in the study scored between the 21st and 60th percentile on measures of
executive function, with the exception of one measure of processing speed, which was at
the 5th percentile. However, when the number of impaired EF scores was examined, all
participants had one or more EF scores 1 or more standard deviations below the
normative mean (16th percentile). Nine of the 13 participants had one or more EF scores 2
standard deviations below the mean or lower (2nd percentile). Regarding self-reported
EF, participants reported elevated levels of emotion dysregulation (DERS: M = 94.31,
SD = 23), impulsivity (BIS: M = 67.92, SD = 8.89), and an elevated tendency to suppress
thoughts (WBSI: M = 53.53, SD = 7.6). EF performance of the sample is provided in
Table 2 (self-report measures) and Table 3 (neuropsychological measures).
Table 3
Neuropsychological Measures of Executive Function
Score
Trails 1
Trails 2
Trails 3
Trails 4
Trails 5
Letter Fluency
Category Fluency
Switching Fluency
Switching Accuracy
Color Naming
Color Word
Inhibition
Switching
List Sorting

M

SD

9.85
9.00
8.38
8.92
10.85
9.08
9.69
8.92
9.08
8.23
9.15
9.15
8.77
93.58

2.30
3.24
4.46
3.35
1.68
3.69
3.12
3.01
2.78
3.27
2.64
3.31
2.28
14.4

Comparison
Mean
Value
Difference
10
-0.24
10
-1.11
10
-1.31
10
-1.16
10
1.82
10
-0.90
10
-0.36
10
-1.3
10
-1.2
10
-1.95
10
-1.16
10
-0.92
10
-1.95
100
-6.42

95% CI

t

df

P value

[-1.55, 1.24]
[-2.96, 0.96]
[-4.31, 1.08]
[-3.10, 0.95]
[-0.17, 1.86]
[-3.15, 1.30]
[-2.19, 1.58]
[-2.90, 0.74]
[-2.60, 0.76]
[-3.75, 0.21
[-2.44, 0.75]
[-2.85, 1.16]
[-2.61, 0.15]
[-15.13, 2.28]

-0.24
-1.11
-1.31
-1.16
1.82
-0.90
-0.36
-1.29
-1.2
-1.95
-1.16
-0.92
-0.24
-1.61

12
12
12
12
12
12
12
12
12
12
12
12
12
12

.814
.288
.216
.269
.094
.384
.728
.222
.255
.075
.270
.375
.075
.134
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Pattern Comparison
Flanker
Card Sort

74.95 15.18
88.62 21.03
96.98 22.19

100
100
100

-25.05
-11.38
-3.02

[-34.22, -15.87] -5.95 12
[-24.09, 1.33] -1.95 12
[-16.43, 10.38] -0.49 12

.000*
.075
.632

Note: M, Mean; S.D. standard deviation; CI, Confidence Interval; df, degrees of freedom.
Significance levels were determined by single sample t tests. Single asterisk (*) signifies
a correlation is significant at the 0.05 level (2-tailed).
Correlations Between Measures of EF. Correlations between D-KEFS’ scores
was examined first. On the TMT, scores between TMT1, TMT2, TMT3 and TMT4 were
all positive correlated (p values: .048 - .001). TMT5 was not significantly correlated
within any other D-KEFS subtests examined (p > .05). On Verbal Fluency subtests, VF2
was positively correlated with VF1 and VF3 (p = .035 and p = .005); VF3 total correct
and switching accuracy were correlated (p = .002). None of the CWI subtests were
correlated (p >.05). Across measures on the DKEFS, VF1 was correlated with TMT4,
CW1 and CW3 (p = .020, p = .044, p = .011, respectively). VF2 was positively correlated
with TMT3, CW3 and CW4 (p = .018, p = .020, p = .048).
Correlations among subtests of the Toolbox were examined next. List Sorting,
Flanker, and Card Sort Scores were all positively correlated (p values = .009 - .001).
Pattern Comparison was not correlated with any Toolbox measure (p > .05).
Correlations between DKEFS scores and NIH scores were examined next. Scores
from the DCS, a measure of shifting, were significantly correlated with DKEFS VF:
Switching Accuracy and VF1 (p = .036 and p = .013, respectively). Scores from the LS, a
measure of working memory, were significantly correlated with DKEFS VF subtests:
category fluency, switching total correct, and category switching accuracy (p = .011, p =
.035, p = .012), as well as, DKEFS CW: shifting (p = .003). Flanker, a measure of
attention and impulse control, was significantly correlated with DKEFS VF switching
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accuracy (p = .013). Scores from the PC, a measure of processing speed, were positively
correlated with DKEFS TMT: Motor Coordination (p = .040).
Lastly, correlations between self-report measures of EF and neuropsychological
measures of EF (NIH Toolbox, D-KEFS: TMT4, VF, CW3 and CW4) were examined
next. While BIS and DERS were elevated, they were not correlated with
neuropsychological measures of EF (all p-values > .05). Follow up analyses examining
correlations between simpler measures of attention and processing speed and self-report
measures of EF. Please see for Table 4 for exact p-values and correlation coefficients.
Table 4. Correlations Between Measures of Executive Function
1 trails1
2 trails2
3 trails3
4 trails4
5 trails5
6 vf1
7 vf2
8 vf3
9 vf3
10 cwi1
11 cwi2
12 cwi3
13 cwi4
14 LS
15 PC
16 FL
17 CS
18 DERS
19 BIS-11
20 WBSI

1
.048
.007
.031
.600
.092
.068
.416
.581
.067
.657
.047
.152
.330
.461
.109
.162
.913
.071
.254

2
.56*
.001
.038
.636
.545
.240
.184
.411
.542
.682
.146
.675
.896
.672
.672
.459
.194
.900
.497

3
.70**
.81**
.003
.856
.095
.018
.079
.445
.204
.971
.055
.229
.255
.386
.331
.130
.360
.538
.654

4
.60*
.58*
.75**
.426
.020
.158
.579
.599
.132
.239
.072
.185
.359
.514
.140
.073
.801
.943
.641

5
-.16
-.15
.06
.24
.256
.917
.284
.343
.996
.059
.929
.631
.299
.040
.084
.213
.884
.436
.692

6
.49
.19
.48
.63*
.34
.035
.568
.877
.044
.239
.011
.284
.165
.670
.068
.036
.690
.734
.209

7
.52
.35
.64*
.42
.03
.59*
.005
.132
.125
.956
.020
.048
.011
.276
.276
.084
.696
.827
.461

8
.25
.39
.50
.17
.32
.18
.73**
.002
.388
.875
.146
.181
.035
.598
.185
.139
.442
.942
.775

9
.17
.25
.23
.16
.29
.05
.44
.77**
.399
.825
.434
.146
.012
.443
.013
.013
.914
.885
.643

10
.52
.19
.38
.44
-.00
.57*
.45
.26
.26
.227
.069
.286
.301
.620
.221
.305
.336
.247
.801

11
.14
-.13
.01
.35
.54
.35
-.02
-.05
.07
.36
.890
.180
.460
.227
.282
.464
.507
.308
.960

12
.56*
.43
.54
.52
.03
.68*
.63*
.43
.24
.52
-.04
.129
.224
.420
.117
.087
.828
.349
.849

13
.42
.13
.36
.39
.15
.32
.56*
.40
.43
.32
.40
.44
.003
.737
.072
.057
.213
.554
.605

14
.30
-.04
.34
.28
.31
.41
.67
.59
.67
.31
.23
.36
.76
.641
.009
.001
.453
.552
.410

15
-.22
-.13
-.26
-.20
.58
-.13
-.33
.16
.23
.15
.36
-.25
-.10
-.14
.482
.679
.642
.858
.435

16
.47
.13
.29
.43
.50
.52
.33
.39
.67
.37
.32
.46
.51
.69**
.48
.000
.384
.201
.176

17
.41
.23
.44
.51
.37
.59
.50
.43
.67
.31
.22
.50
.54
.81**
.68
.90**
.679
.520
.093

18
0.03
-0.39
-0.28
-0.08
-0.05
-0.12
-0.12
-0.23
-0.03
-0.29
-0.20
0.07
0.37
0.23
-0.14
0.26
0.13
.098
.733

19
0.52
0.04
0.19
0.02
-0.24
0.10
0.07
-0.02
0.05
0.35
-0.31
0.28
0.18
0.18
0.06
0.38
0.20
0.48
.640

20
0.34
0.21
0.14
0.14
-0.12
0.37
0.22
-0.09
0.14
-0.08
-0.02
0.06
0.16
0.25
-0.24
0.40
0.49
0.11
0.14
-

Note: M, Mean; S.D. standard deviation; CI, Confidence Interval; df, degrees of freedom;
vf1, Verbal Fluency: Letter Fluency; vf2, Verbal Fluency: Category Fluency; vf3; Verbal
Fluency: Switching Fluency; vf3a, Verbal Fluency: Switching Fluency Accuracy; cwi1,
Color Word Inhibition: Word Reading; cwi2, Color Word Inhibition: Word Reading;
cwi3: Color Word Inhibition: Inhibition; cwi3, Color Word Inhibition: Switching; LS,
List Sorting; PC, Pattern Completion; FL, Flanker; CS, Card Sort; BIS, Barrett
Impulsivity Scale; WBSI, White Bear Suppression Inventory; DERS, Difficulties in
Emotion Regulation Scale. The upper values represent Spearman’ rho and the lower
corresponding p values. Significance levels were determined by Spearman’s Rank Order
correlations. Single asterisk (*) signifies a correlation is significant at the 0.05 level (2tailed). Double asterisk (**) signifies a correlation is significant at the 0.01 level (2tailed).
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Exploratory Analysis: Correlations Between EF and Symptoms. Self-report
measures of worry (PSWQ), perceived stress (PSS), and depressed mood (BDI) were
generally not correlated with neuropsychological measures of EF. BDI was positively
correlated with performance on color word inhibition switching (rs = .604, p = .049) and
Pattern Comparison was negatively correlated with State Anxiety (rs = -0.636, p = .026).
However, DERS total score was positively correlated with BDI (rs = 0.756, p = .007),
PSWQ (rs = 0.715, p = .006), STAI-Trait (rs = 0.783, p = .003), and PSS (rs = .742, p =
.004). WBSI was correlated with BDI (rrs = .689, p = .019). No significant correlations
were observed between DERS total, WBSI, or BIS (all p values < .05) and or between
BIS and measures of mood or anxiety.
Use of substance of abuse in the past 90 days was positively correlated with Trails
4 (rs = 0.599, p = .031). Use of any substance was negatively correlated with card sorting
(rs = -.611, p = .027). No significant correlations between use and measures of mood or
self-reported EF were found (all p-values > .05). Please see Table 5 for correlations
between EF and self-report measures of mood, anxiety, mindfulness and substance use.
Table 5
Correlations between Executive Function and Symptom Measures

EF

BDI-2

PSS

PSWQ

STAI-S

STAI-T

KMIS

MAAS

VAS

ADCQ+

ADCQ-

1

0.15
0.621

-0.12
0.692

-0.29
0.342

-0.01
0.964

-0.19
0.546

0.06
0.851

0.1
0.752

-0.42
0.176

-0.39
0.185

0.23
0.452

2

-0.09
0.777

-0.18
0.565

-0.34
0.252

0.05
0.87

-0.3
0.344

0.52
0.07

0.21
0.485

-0.28
0.38

-0.19
0.54

-0.04
0.91

3

-0.03
0.936

-0.18
0.556

-0.4
0.17

-0.06
0.862

-0.19
0.555

0.21
0.499

0.26
0.399

-0.09
0.785

-0.32
0.29

-0.15
0.619

4

0.08
0.804

0.01
0.975

-0.26
0.397

0.02
0.943

0.16
0.622

0.22
0.478

0.12
0.704

0.16
0.621

-0.23
0.443

0
0.993

5

-0.29
0.345

-0.38
0.207

-0.02
0.95

-.61*
0.034

0.01
0.981

-0.05
0.868

-0.06
0.845

0.08
0.814

.64*
0.019

0.18
0.553

6

0.01
0.964

-0.33
0.265

-0.24
0.436

-0.33
0.303

-0.04
0.905

-0.12
0.709

-0.37
0.211

0.27
0.401

-0.05
0.863

-0.03
0.917
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0.1
0.747

-0.15
0.62

-0.39
0.186

-0.11
0.744

-0.14
0.675

-0.15
0.617

0.02
0.949

0.18
0.578

-0.34
0.257

-0.31
0.297

-0.19
0.535
0.08
0.807

-0.27
0.374
0.01
0.986

-0.37
0.216
-0.01
0.975

-0.51
0.091
-0.36
0.245

-0.28
0.383
0.14
0.668

0.09
0.771
-0.13
0.669

0.17
0.591
-0.16
0.61

-0.21
0.522
-0.16
0.618

0.06
0.838
0.19
0.53

0
0.993
0.29
0.345

10

-0.16
0.594

-0.27
0.375

-0.47
0.107

-0.42
0.17

-0.27
0.401

0.17
0.589

0.02
0.961

-0.27
0.403

-0.11
0.72

0.34
0.257

11

-0.17
0.591

-0.5
0.082

-0.4
0.181

-0.2
0.544

-0.15
0.635

-0.02
0.96

0
0.989

0.08
0.817

.59*
0.034

0.36
0.227

12

0.15
0.624

-0.09
0.771

-0.3
0.327

-0.3
0.353

0.02
0.956

0.27
0.374

-0.27
0.381

-0.1
0.75

-0.39
0.193

0.21
0.499

13

.60*
0.031

0.12
0.728

-0.09
0.783

0.23
0.479

0.36
0.257

-0.25
0.415

-0.12
0.707

0.15
0.652

-0.15
0.62

0.07
0.823

14

0.42
0.159

0.06
0.847

0.02
0.947

-0.06
0.858

0.36
0.249

-.59*
0.035

-0.31
0.311

0.25
0.435

-0.04
0.889

0.01
0.964

15

-0.4
0.171

-0.36
0.223

0.04
0.901

-.64*
0.026

-0.29
0.354

0.24
0.423

0.12
0.686

-0.47
0.127

.67*
0.012

0.42
0.158

16

0.28
0.348

-0.04
0.907

0.2
0.523

-0.41
0.184

0.34
0.276

-0.31
0.307

-0.49
0.093

-0.17
0.594

0.17
0.587

0.48
0.094

17

0.35
0.243

0
1

0.12
0.705

-0.2
0.529

0.42
0.171

-0.42
0.156

-.56*
0.049

0.13
0.68

0.05
0.864

0.22
0.467

18

40
0.176

0.33
0.271

0.39
0.19

-0.04
0.901

0.23
0.47

-0.19
0.538

-0.12
0.689

-0.46
0.129

-0.48
0.1

0.28
0.36

19

.78**
0.002

.74**
0.004

.72**
0.006

0.41
0.184

.78**
0.003

-0.4
0.184

-0.23
0.446

0.15
0.64

-0.43
0.146

0.05
0.865

20

0.45
0.126

0.01
0.982

0.37
0.217

0.34
0.286

0.23
0.468

-0.53
0.063

-.59*
0.035

0.23
0.482

0
0.996

-0.21
0.497

7
8
9

Note: EF, Executive Function Variable; BDI-2, Beck Depression Inventory; PSS,
Perceived Stress Scale; PSWQ, Penn State Worry Questionnaire; State Trait Anxiety
Inventory-State, STAI-S; STAI-T, State Trait Anxiety Inventory-Trait; KIMS-T,
Kentucky Inventory of Mindfulness Skills- Total; MAAS, Mindful Attention Awareness
Scale; VAS, Visual Analogue Scale; ADCQ, Alcohol and Drug Consequences
Questionnaire; 1, Trails 1; 2, Trails 2; 3, Trails 3; 4, Trails 4; 5, Trails 5; 6, Verbal
Fluency: Letter Fluency; 7, Verbal Fluency: Category Fluency; 8; Verbal Fluency:
Switching Fluency; 9, Verbal Fluency: Switching Fluency Accuracy; 10, Color Word
Inhibition: Word Reading; 11, Color Word Inhibition: Word Reading; 12, Color Word
Inhibition: Inhibition; 13, Color Word Inhibition: Switching; 14, List Sorting; 15, Pattern
Completion; 16, Flanker; 17, Card Sort; 18, Barrett Impulsivity Scale; 19, White Bear
Suppression Inventory; 20, Difficulties in Emotion Regulation Scale. Significance levels
were determined by Spearman’s Rank Order correlations. The upper values represent
Spearman’ rho and the lower values represent the corresponding p values. Single asterisk
(*) signifies a correlation is significant at the 0.05 level (2-tailed). Double asterisk (**)
signifies a correlation is significant at the 0.01 level (2-tailed).
Specific Aim 4: Examine Topological Properties of fNIRS Resting State Networks
Connectivity matrices were generated for HbO, HbR, and HbT maps for each
participant and at the group level. A sparsity threshold (number of existing edges:
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maximum number of edges possible) was applied to remove spurious correlations
between channels. Each participants’ connectivity matrices were empirically thresholded
over a range of 0.1<sparsity<0.5 (interval 0.01) to create sparse, positive binary networks
Please see Figure 2 for an example.
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Figure 2. Example connectivity matrices across sparsity thresholds. Example fNIRS
resting-state functional connectivity matrix at the individual level (right) and group level
(left) calculated using Pearson Correlation Coefficients (A) and corresponding matrices at
varying sparsity thresholds (B).
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Topological properties of the network were then calculated across sparsity
thresholds. For the purposes of this study, the analyses were limited to eight metrics
generated from the HbO maps: five measures reflecting small world properties; two
measures of efficiency (network efficiency and local efficiency), and one measure at the
nodal level (degree centrality). Area Under Curve (AUC) values were examined for
small world metrics and efficiency metrics from the HbO, HbR, and HbT maps.
Across sparsity thresholds, small world network parameters were generally
supported. Small Worldness is detected in networks where Gamma (γ) was greater than
1, Lambda (λ) at or slightly greater than 1, and was Sigma (σ) greater than 1. Clustering
coefficient (Cp) varied across thresholds (M 0.43= at 0.1 to Mean = 0.71 at .4). The ratio
of the clustering coefficient of the network to the clustering coefficient of the random
network (gamma), at a given threshold, however was greater than 1 across thresholds (M
= 1.97 at 0.1; M = 1.17 at 0.4). The shortest path length (Lp) varied across sparsity
thresholds (M = 4.51 at 0.1; M = 1.47 at 0.4). The ratio of the shortest path length of the
network to the shortest path length in randomly generated networks (lambda), was
slightly above 1 across thresholds (M = 1.27 at 0.1; M =1.03 at 0.4). Finally, sigma (ratio
of gamma to lamba) in the network was greater than 1 across thresholds (M = 1.59 at .01;
1.14 at 0.4), meaning the network has greater than random clustering and near random
path length. Small world metrics across sparsity thresholds are displayed in Figure 3.
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Figure 3.Small World Metrics. Results of clustering coefficient (A), shortest path length
(B), Gamma (C), Lambda (D), and Sigma (E) areas as a function of sparsity threshold.
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Global efficiency (eg) varied across thresholds (M = 0.24 at .1; M = 0.63 at .4) as
did local efficiency (Eloc) (M = 0.51 at .1; M = 0.81 at .4). Degree centrality was
calculated for each node using AUC scalar value. Mean degree Centrality across all
channels was 9.48 (SD = 5.47). Network Efficiency metrics across sparsity thresholds
are displayed in Figure 4.
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Finally, the AUC for the five small world metrics and two efficiency metrics were
examined in the HbO, HbR and HbT maps separately. AUC values for each of the seven
metrics calculated for each map are displayed in Figure 5.
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Figure 5. Area Under Curve (AUC) values for network measures: Sigma, clustering
coefficient (Cp), Gamma, Lambda, shortest path length (Lp), global efficiency (Eg), and
local efficiency (Eloc). Color bars represent: HbO, oxy-hemoglobin; HbR, deoxyhemoglobin; and HbT, Total-hemoglobin.

Correlations between seven graph metric variables (AUC scalar variables for
Gamma, Sigma, Lambda, Cp, Lp, Eg and Eloc) calculated from the HbO maps and EF
measures were examined. Color word inhibition score was negatively correlated with
aSigma (r = -.590, p = .044). Trails 1 scaled score was negatively correlated with aSigma
and aGamma (r = -.600, p = .038; r = -.725, p = .008). No correlations were observed for
the NIH toolbox tests. Total scores for self-report measures of EF were examined next.
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BIS total score was negatively correlated with aSigma and aGamma (r = -.708, p = .01
and r = -.636, p = .026). Total score on the WBSI was negatively correlated with local
efficiency (aEloc) (r = -.597, p = .040).
An exploratory follow up analysis examining correlations between BIS subscales
and the seven graph metrics (Gamma, Sigma, Lambda, Cp, Lp, Eg and Eloc) was
conducted. Of the second level factors (Attention, Motor, and Planning), the BIS Motor
Scale was negatively correlated with aSigma and aGamma (r = -.752, p = .005; r = -.689,
p = .013). Across subscales, the BIS perseverance subscale was negatively correlated
with aSigma and aGamma (r = -.814, p = .001 and r = -.788, p = .002), and the BIS
cognitive instability, a subscale of Planning, was positively correlated with shortest path
length (aLp) r = .601 (p = .039). See Table 6 for exact correlations and p-values.
Table 6
Correlates between EF and Graph Metrics
Measure
Trails 1

VF 2: Category
Fluency

Sigma
-.60*
.039
-.12
.709
-.36
.257
-.27
.397
.06
.857
-.29
.366
-.22
.500

Cp
-.12
.705
-.14
.674
.17
.590
-.21
.516
-.07
.828
.12
.706
.37
.236

Gamma
-.73**
.008
-.27
.399
-.32
.309
-.27
.395
.37
.240
-.35
.260
-.18
.572

Lambda
.28
.373
-.14
.669
.27
.405
.15
.643
.49
.107
.24
.444
.19
.563

Lp
.31
.328
-.09
.785
.03
.922
-.11
.728
.05
.890
.33
.291
.20
.534

Eg
-.30
.342
.22
.493
.06
.844
.14
.662
.00
.991
-.43
.169
-.35
.267

Eloc
-.41
.181
-.08
.810
.02
.948
-.02
.944
.24
.455
-.20
.540
-.13
.690

VF 3: Switching
Fluency

-.10
.754

.31
.331

.13
.692

.33
.293

.18
.581

-.17
.592

.03
.930

Trails 2
Trails 3
Trails 4
Trails 5
VF 1: Letter Fluency
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VF 3: Switching
Accuracy
CWI 1: Color Naming

-.10
.759
-.15
.639
CWI 2: Word Reading .33
.302
CWI 3: Inhibition
-.59*
.04
CWI 4: Switching
-.082
.800
List Sorting
-.19
.548
Pattern Comparison
.20
.527
Flanker
-.48
.111
Card Sort
-.32
.309
DERS
-.47
.124
BIS-11
-.71*
.010
WBSI
-.05
.866

-.13
.689
.27
.395
-.22
.503
.27
.40
-.105
.746
.10
.759
-.22
.500
-.34
.285
-.15
.650
-.38
.229
-.05
.870
-.51
.088

.07
.827
-.20
.540
.26
.410
-.50
.10
.000
1.000
.01
.966
.32
.319
-.36
.255
-.23
.467
-.32
.319
-.64*
.026
-.46
.129

.22
.485
.22
.499
.18
.576
.44
.16
.218
.495
.40
.193
.10
.770
.47
.121
.34
.276
.13
.688
.30
.353
-.48
.119

.00
.991
.000
1.000
-.36
.252
.50
.10
-.156
.628
.01
.974
-.03
.931
.31
.331
.12
.711
.30
.354
.46
.131
.12
.720

-.00
.991
-.11
.740
.27
.400
-.50
.10
-.036
.911
-.14
.656
.03
.940
-.32
.318
-.14
.662
-.38
.221
-.46
.134
-.27
.401

-.07
.826)
.10
.756
.34
.276
-.30
.35
-.013
.969
.01
.965
.10
.761
-.34
.279
-.16
.622
-.50
.099
-.47
.120
-.60*
.040

Note: VF, Verbal Fluency; CWI, Color Word Inhibition; BIS, Barrett Impulsivity Scale;
WBSI, White Bear Suppression Inventory; DERS, Difficulties in Emotion Regulation
Scale; Cp, clustering coefficient; Lp, shortest path length; Eg, global efficiency; Eloc,
local efficiency. Significance levels were determined by Spearman’s Rank Order
correlations. In each cell, the top value represent Spearman’ rho and the lower value
represents the corresponding p value. Single asterisk (*) signifies a correlation is
significant at the 0.05 level (2-tailed). Double asterisk (**) signifies a correlation is
significant at the 0.01 level (2-tailed).
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DISCUSSION
The primary aim of the study was to assess the feasibility of implementing a pilot
RCT of MBRP within an outpatient substance use and methadone clinic from a
neuropsychological framework. The continued increase in opioid overdose death rates in
the United States is of grave concern and the need for additional treatments to better
serve individuals with OUD cannot be understated. While recruitment efforts were
targeted to adolescents and young adults, only young adult participants were successfully
recruited. The feasibility of using both neuropsychological measures of EF and fNIRS,
in addition to measures of substance use and mood, in the context of a RCT was
demonstrated. The recruited sample demonstrated more variability in substance use
history, more severe markers of psychopathology and greater unemployment rates than
expected. However, none of the baseline variables measured was associated with
attendance of the follow up session, with the exception of number of prescribed
psychiatric medications. Overall, measures of executive function were within normal
limits relative to the normative data, with the exception of one measure of processing
speed. When EF performance variability was examined, however, a significant
proportion of the sample had several scores in the impaired range, supporting the notion
that EF is a multifactorial construct that may be best captured with multiple measures.
This finding was supported by the limited number of significant correlations identified
between the different measures of EF assessed in the study. Finally, resting state
functional connectivity networks were successfully measured using fNIRS. Preliminary
findings provided support for identifying small world networks using fNIRS.

69
The distinction between feasibility in a logistical sense and feasibility of the
scientific methods employed in this study is worthy of consideration. Significant
logistical constraints impacted the implementation of the study, including limitations in
staff involved in study procedures, shifting between locations, and challenges related to
retention. While these constraints impacted the overall sample size and power to detect
changes, the scientific methods utilized were found to be feasible. EF was measured
using several reliable and valid instruments; multiple clinical symptom measures were
administered; fNIRS was successfully used to collect resting state network data; and
topological properties of resting-state networks were identified with fNIRS data. Further,
the treatment intervention was successfully implemented and randomization did not
appear to impact follow-up rates.
Feasibility Issues: Recruitment and Retention
20 participants were consented, 13 participants were randomized to condition, and
six participants completed through to the follow-up visit. While no specific baseline
characteristics were found to be predictive of attendance of follow-up visit, with the
exception of psychiatric medication use, continued care at the facility throughout the
study was likely a contributing factor. While patients receiving care at a methadone
clinic are in many ways a “treatment seeking” population, the level of motivation and
interest for additional behavioral treatments within this population is unknown.
Motivation and readiness to make behavioral changes, on any level, fluctuates throughout
the course of a given day or stage in behavior change. This is natural and expected. While
a significant number of individuals present to the clinic daily for ORT, appearing to the
clinic for ORT may not be not be synonymous with seeking additional intervention.
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Adolescents remain a population that underutilizes treatments for OUD. There is
a significant need for treatments that target younger individuals. In this study,
individuals under the age of 18 were not recruited despite significant efforts to target this
subset of the treatment population, specifically. In part, the reduced flow of adolescent
patients in the clinic and the increased severity of symptoms among those that were
receiving care at the time of the study are likely contributing factors. However, there
were some adolescents and families that did receive care at the clinic and were not
interested in additional options. It is possible that at the time of study contact, a relapseprevention framework was not an appropriate clinical fit. Clients experiencing
withdrawal, currently being stabilized on an ORT, or still experiencing significant
ambivalence about making changes in opioid use behaviors would not be a good fit for a
relapse prevention program. Nonetheless, it would be helpful to better understand what
factors impact treatment engagement among adolescents. One way to address this would
be via qualitative methodology.
A qualitative approach may help to better identify barriers to treatment perceived
by adolescents and their family members. Clearly, developing treatments that target
adolescents are needed and understanding what factors impact engagement is a good first
step. The majority of participants recruited in this study began using substances in their
teens, yet on average there was nearly an 8-year lag between first use and first treatment
encounter. A better understanding from their perspective would also help identify factors
that may have motivated eventual engagement in services. Increased effort to gain
support from family members would likely increase treatment engagement among
adolescents, as well. Perhaps this could be accomplished via a brief presentation to
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parents and family members at possible clinic orientation sessions. Since the vast
majority of the recruited sample reported their first encounter with mental health
providers occurred during adolescence, perhaps targeting substance use interventions to
adolescents receiving mental health treatment might be a useful approach.
Approximately, half of the sample attended the final follow up session. With the
exception of number of psychiatric medications prescribed, none of the baseline variables
measured were found to be significantly associated with attendance at the follow up
session. Given the small sample size, power to detect small to medium effect sizes was
limited. Consistent care within the treatment facility, however, did appear to be an
important factor for follow-up attendance.
Clinical Characteristics of the Recruited Sample
The recruited sample demonstrated variability in substance use history, severe
markers of psychopathology, and significant unemployment rates. Most of the sample
reported use of two or more substances when using their drug of choice, and over three
quarters of the sample reported a history of concurrent abuse of opioid and stimulants.
Substance use disorders are diagnosed by drug of abuse and consequently, treatment
outcomes both clinically and in research contexts focus on the identified drug of abuse.
This approach does not fully capture substance use patterns among all individuals with
SUD. In particular, it fails to capture polydrug use, comorbid SUDs, and development of
later SUDs during the course of care.
Approximately, one third of the sample reported using the substance of abuse in
the past 90 days, however, nearly three-quarters of the sample reported use of a different
substance of abuse. This finding highlights the complexity of assessing treatment
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outcomes in this population. Methods for how to handle and detect the occurrence of new
“addictions” during the course of treatment are needed. Abuse of prescription
medications, alcohol or marijuana may emerge during the course of ORT treatment. A
significant portion of the sample reported use of cannabis, as well as nicotine. Instances
of using prescribed medications in ways that were not prescribed, was also reported.
Identifying the best treatment targets can be a dynamic process. Over the course
of treatment, it may be necessary to reassess substance use patterns periodically. While a
harm reduction approach makes sense at initiation of treatment, as clients become
stabilized on an ORT, new substances of abuse may become increasingly problematic.
As mentioned, many of the participants reported use of cannabis. Notably, there have
been efforts to use cannabis as a treatment for OUD and it has been added to the list of
conditions for which medical marijuana may be prescribed in New Mexico (Kunkel,
2019). While from a harm reduction perspective this may prevent overdose deaths, it
also has the potential to foster additional substance use disorders. The latest research also
suggests cannabis may not be associated with reduced overdose deaths in the long run
(Shover, Davis, Gordon, & Humphreys, 2019) and may be associated with increased
psychosis (Shover, Shoptaw, et al., 2019). Perhaps, effort to develop new behavioral
treatments for OUD might be a better use of resources.
The prevalence of comorbid psychopathology was well documented in this
sample. All participants reported being diagnosed with at least one additional psychiatric
disorder and a significant proportion were on multiple psychotropic medications in
addition to ORT or naltrexone. While there was a significant lag between initiation of
substance use and first encounter with substance use treatment, participants had a history
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of early mental health treatment. In fact, the average age for first drug use and first
mental health encounter were within the same 12-month period. Continued difficulty
with mental health symptoms was reported at the time of the study as well, with
participants reporting symptoms of anxiety and low mood. This finding highlights the
need for interventions that can address the complex comorbid mental health issues that
often arise among individuals with OUD. Further, the self-report measures of EF
included measures of emotion regulation and coping strategies. Participants reported
reduced coping strategies and impaired ability to regulate emotions, providing additional
support for the future use of MBRP in this population. As previously mentioned, MBRP,
in particular, has been shown to be helpful with aspects of emotion regulation.
Executive Functioning at Start of Study
When compared to the normative sample, at a group level, participants in the
study scored within between the 21st and 60th percentile on measures of executive
function, with the exception of one measure of processing speed, which was at the 5th
percentile. However, when the number of impaired EF scores was examined per
participant, a significant proportion of the sample had one or more scores in the impaired
range (below the 5th percentile). This finding supports the idea of EF as a multifactorial
construct that is not easily measured by a single test or score. Non-significant
correlations between measures of EF within this sample provide tentative further support
for using multiple measures of EF to capture EF impairments. In future work, it would be
helpful to generate a single measure of EF in addition to measures of specific EFs. In
larger samples this could be done using a principal components analysis or by averaging
standardized scores. The EF tests selected for this study captured a range of EFs,
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however, in future work it may be useful to limit analyses to scores that capture the most
demanding aspect of the task (e.g., Trails 4, but not Trails 1, 2, 3 and 5; color word
inhibition and color word inhibition switching, but not color naming and word reading).
Interestingly, while self-reported EF problems were not correlated with
performance on objective measures of EF, there were some correlations between selfreport measures of EF and measures of mood and anxiety. The relationship between selfreported EF problems and other symptom measures has been examined in other
populations, such as mild Traumatic Brain Injury (Rapoport, McCullagh, Shammi, &
Feinstein, 2005; Schiehser et al., 2011). It may be useful to consider self-reported EF in
the context of other mental health conditions in future research. In particular, in the
treatment studies, it would be interesting to assess if treatment response to self-report
measures of EF differs from treatment response to objective measures of EF.
Additional measures of EF, not used in the current study should be explored in
future work. Specific to cool EFs, measures of planning, such as the Tower of London
and measures of sustained attention would be informative. The variability in
performance across measures of EF could, in part, be explained by a weakness in
sustained attention. It is also possible that the variability in performance across tests
could be explained by effort. In future studies, an objective measure of effort would be
very informative.
Finally, hot EF tasks seem particularly relevant for this population. There were
challenges associated with administering a hot EF task in this study. Hot EF tasks,
including the one used in this study, can be time consuming. This can pose a real
challenge for researchers administering a larger battery of cool EF tasks. In this study,
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the hot EF task was administered last in the sequence of measures to prevent the hot EF
task from influencing performance on the cool EF tasks. This could theoretically impact
skew performance on the hot EF task if individuals are more fatigued when the hot EF
task is administered. Among clinical samples it is important to consider when the task
might be too distressing for a given participant, as well. It would be helpful to develop a
standardized procedure for determining if a task is too distressing for participants.
Similarly, a set of standardized procedures for follow-up support for participants after the
task would be worth further consideration. Additional hot EF tasks should be explored in
this population as well. Tasks that capture decision-making and delayed discounting, for
instance, would be particularly relevant for SUD treatment samples. Likewise,
administering EF tasks with embedded drug-cues would further our understanding of EF
in the context of triggers to use substances. While hot EF tasks are relatively new in the
field of EF research, these tasks have the potential to capture the real-world impairments
of EF that may not always be captured by cool EF measures.
In future research it would be helpful to tie specific EF impairments to functional
outcomes. For instance, perhaps an individual with impaired fluency might exhibit
greater difficulty generating new solutions to a problem. Alternatively, perhaps an
individual with difficulty shifting on tasks of EF might demonstrate difficulties
transitioning between home and work. It is important that one can connect impairments in
EF in daily life with the EF impairments observed on study measures.
fNIRS is Both Feasible and Useful
Findings supported the presence of small world properties in the fNIRS resting
state networks in this study. Exploratory analyses examining correlations between
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network results and measures of EF, as well as, measures of mood, anxiety, substance
use, and mindfulness were successfully performed. This provides support that fNIRS can
be utilized in clinical research in very meaningful ways. fMRI research is very costly,
yet provides important metrics for furthering our understanding of mental health
problems. Resting state analyses, in particular have shown potential for meaningful
clinical applications. While fMRI research is still needed to examine subcortical resting
state networks, fNIRS proves to be an effective and relatively inexpensive alternative.
As was demonstrated in this study, fNIRS can be used successfully to generate these
more complex network analyses and can easily be used to examine clinical correlates.
The current montage was selected to capture resting-state activity across the entire
cortex. While minor modifications could be explored (e.g., including additional channels
in the prefrontal cortex and motor cortex) the general approach to montage creation was
supported. Further, while not explicitly examined in these analyses, fNIRS can be used
to examine specific neuroanatomical regions, as well. For instance, one could select
specifically the nodes localized in the frontal regions for a ROI analysis. FC-NIRS
toolbox can detect directed graphs and weighted graphs, as well. These analyses would
be particularly relevant for measuring networks during tasks. Lastly, alternative analytic
approaches could be applied to the fNIRS network as well, such as Independent
Components Analysis.
Finally, while the power was limited, some findings were interesting and worthy
of consideration in future research. First, small world network metrics were successfully
detected using fNIRS. These parameters have been used to identify potential biomarkers
of a variety of psychiatric conditions, including SUD. Changes in small world metrics
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would be an excellent target for treatment that can be captured by fNIRS and could be
emphasized in an RO1 application. Additionally, some preliminary correlations between
the graph metrics and self-reported EF were observed. Specifically, scores on a measure
of impulsivity (BIS-2) was correlated with Gamma and Sigma, two metrics associated
with small worldness. As mentioned earlier, a previous study of MBRP in OUD, found
improvements on the BIS-2 in the MBRP group, but not the control group (Yaghubi,
Zargar, & Akbari, 2017). Perhaps, one potential mechanism for a reduction in
impulsivity following MBRP is via increased small worldness in the resting state
network.
Limitations
The small sample size recruited and the drop-out rate were significant study
limitations. The impact of the MBRP on substance use, executive functioning, and
resting state connectivity could not be determined. Regarding measures, self-report
measures of substance use are less reliable than objective measure of substance use, such
as might be found from a urine analysis. Additionally, the study did not gather
qualitative information from study participants, which could have guided future work.
Finally, the participants recruited were heterogeneous in terms of comorbid psychiatric
diagnoses, substance use history, and psychiatric medications. While homogenous, i.e.,
“clean”, samples are the gold standard during initial RCTs, often the clinical reality is one
of greater complexity and heterogeneity.
Conclusions
Pilot studies can help inform larger studies. Understanding the steps needed to
implement an empirically supported treatment into different outpatient clinics is a
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necessary step in the dissemination of research. The protocol was already modified for a
treatment setting, which increased the feasibility greatly (Roos, 2019). More specifically,
sessions were briefer, offered multiple times a week, and a rolling group format was
utilized. Frequently, providers express frustration or reluctance to adopt manualized
protocols because there is a belief that clinical trials are not conducted in the “real
world”. Fortunately, robust treatments, such as MBRP, can withstand more complex
populations. Additional staff would be needed to successfully run this study at a larger
scale. More specifically, it would be beneficial to have a least one part time staff member
(i.e. study coordinator) on site at the clinic to facilitate continued contact with clinic staff
and interested participants. Additionally, it would be helpful to have a second staff
member present for active recruitment periods (i.e., during peak traffic times at the
clinic). For baseline visits, two to three additional research assistants would enable
participants to complete baseline measures more efficiently and would allow for multiple
participants to be scheduled at once. Regarding therapy groups, ideally bi-weekly groups
would be available at multiple time slots (i.e., four time slots) to capture both the morning
wave and afternoon wave of participants. This would likely require three to four
therapists. Lastly, for an RO1 application, a case manager or social worker on staff to
help with patient care coordination would be helpful and a psychiatrist or psychiatric
nurse (0.25 FTE) would be helpful to have on site in the event of any medical crises (e.g.,
overdose).
Prevention and early intervention efforts are paramount. The majority of
individuals within this study began using substances in their teens, yet on average there
was nearly an 8-year lag between first use and first treatment encounter. Clearly,
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developing treatments that target adolescents are needed. The vast majority of the sample
first experienced mental health issues in their teens as well. Specific targeted prevention
efforts should be implemented within pediatric mental health clinics. Additionally, more
in depth assessment of substance use should be included in every mental health intake
conducted in pediatric health settings. Efforts to educate teachers and parents on
substance use prevention should begin during elementary school given the early age of
first substance use initiation. Finally, preventive interventions that boost EF, such as a
modified MBRP, could be implanted in school systems and are worth future
consideration.
A neuropsychologically-informed approach is feasible. At its core,
neuropsychology is the study of brain-and-behavior relationships. The NIMH created the
RDoC framework to further a dimensional approach to mental health, linking specific
behavioral dysfunctions to specific neural circuits, reflecting a neuropsychological
approach to mental health. Clinical Neuropsychology, as discipline, serves multiple roles
including: development of treatment plans, formulation of accommodations needed to
help an individual function, and in some contexts, prediction of treatment outcomes
(Schoenberg, 2011). While perceived cognitive deficits motivate referrals to
neuropsychology, psychological symptoms are a consistent part of the clinical
presentation. Neuropsychology can make significant contributions in furthering our
understanding of complex mental health conditions like SUD.
Advances in neuroimaging, in conjunction with a long history of clinical
assessment, enables neuropsychology as a field to identify novel treatment targets for
OUD. Further, neuropsychology is well suited to assess treatment-induced changes on
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validated, specific treatment targets over time through the use of neuropsychological
assessments and neuroimaging methods. An integration of neuropsychology with more
traditional clinical trials research for mental health conditions like SUD is a worthy
endeavor. While neuropsychological methods are often time consuming, the findings in
this study demonstrate this approach is not only feasible, but has the potential to link
behavioral symptoms with neural circuits via fNIRS.
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